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ABSTRACT 
 
 
The mouse agouti protein is transiently expressed in the skin and signals 
through the melanocortin 1 receptor to switch pigment production of hair-follicle 
melanocytes from black to yellow. Ubiquitous over-expression of agouti protein 
in mice carrying the spontaneous dominant mutations Ay and Avy causes a 
pleiotropic syndrome characterized by solid yellow hair color, obesity, diabetes, 
and increased susceptibility to carcinogenesis in a wide variety of tissues, 
including the skin. Over-expression of agouti in the skin of keratin 14 (K14)-
Agouti transgenic mice promotes skin carcinogenesis, even in the absence of 
obesity and diabetes. In this study cDNA microarray and qRT-PCR analyses are 
used to identify molecular changes in the skin of K14-Agouti mice associated 
with the promotion stage of carcinogenesis. Histological analysis of the skin 
revealed that there were no differences in gross morphology or in timing of hair-
follicle stages between transgenic and control mice. However, cDNA microarray 
analysis identified 181 genes with significantly altered expression levels in the 
skin of transgenic mice. Additionally, qRT-PCR analysis demonstrated that the 
levels and temporal patterns of expression of 10 genes previously associated with 
skin and/or other epithelial cancers were significantly altered in the skin of K14-
Agouti transgenic mice. Agouti-induced over-expression of these proto-
oncogenes in the skin of K14-Agouti mice is proposed to be associated with the 
increased susceptibility to skin carcinogenesis. A hypothetical model is presented 
to explain the mechanism of action of the agouti protein as a tumor promoter in 
skin carcinogenesis. Additionally, strategies for future follow-on experiments to 
further investigate the role of agouti in tumor promotion and to test aspects of 
the proposed hypothetical model are discussed.  
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CHAPTER I 
 
BACKGROUND AND SIGNIFICANCE 
 
Agouti is a paracrine-acting signaling molecule that is normally expressed 
only in the skin of mice, where it regulates coat color pigmentation. Ubiquitous 
over-expression of wild-type agouti protein in mice carrying spontaneous 
dominant agouti mutations results in solid yellow hair color, obesity, diabetes, 
and increased susceptibility to carcinogenesis in a wide variety of tissues, 
including the skin. In transgenic mice in which the agouti protein is over-
expressed in the skin under the regulatory control of the keratin 14 promoter 
(K14-Agouti mice), body weight and blood glucose levels are normal, but 
transgenic mice are significantly more susceptible to skin cancer and it was 
shown that agouti acts as a tumor promoter in two-stage skin carcinogenesis 
experiments. The goal of this study was to determine the molecular level changes 
associated with the promotion stage of skin carcinogenesis in the uninitiated skin 
of K14-Agouti mice. Since tumor promotion is a reversible and rate-limiting step 
in carcinogenesis, understanding the molecular changes associated with tumor 
promotion may lead to strategies for the treatment and prevention of cancer. 
Microarray and qRT-PCR experiments were performed to determine the 
expression profiles of genes in the skin of K14-Agouti and control mice at 
different ages and at different stages of the hair-follicle cycle. Genes known to be 
associated with skin cancer and other epithelial cancers are shown to be up-
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regulated and to have altered temporal expression profiles in the skin of K14-
Agouti transgenic mice. It is proposed that these gene expression changes 
underlie the increased susceptibility of K14-Agouti mice to skin carcinogenesis. 
A testable model that synthesizes the data obtained in this study is presented to 
explain the mechanism of action of the agouti protein as a tumor promoter in 
skin carcinogenesis. 
 
THE MOUSE NONAGOUTI LOCUS 
     
 The nonagouti locus (a), which is located on mouse chromosome 2, 
regulates the pigmentation pattern in the hairs of mice. The transcript of the 
nonagouti locus (referred to as the agouti gene hereafter) is normally expressed 
only in the skin and encodes a 131 amino acid (aa) signal peptide. The agouti 
protein acts in a paracrine fashion in the microenvironment of hair follicles [1, 2]. 
In wild-type mice, the agouti protein is secreted from cells of the dermal papillae 
during the mid-portion of the hair-growth cycle [3, 4].  Agouti protein competes 
with alpha-melanocortin stimulating hormone (α-MSH) for binding to the 
melanocortin 1 receptor (MC1R) on the surface of melanocytes [5]. In response to 
agouti signaling through MC1R, melanocytes switch from eumelanin 
(black/brown) pigment production to phaeomelanin (yellow/red) pigment 
production.  As a result of this switch mechanism, individual hairs of wild-type 
mice have an agouti pigmentation pattern, which consists of a subapical yellow 
band in an otherwise black hair.  
 
 An interest in the coat colors of mice can be traced back thousands of 
years in China to the first domestication of “fancy mice” that had spontaneous 
mutations in various coat-color genes. The mouse fancy gained in popularity 
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during the 1700s and 1800s in Japan and Europe, when mice with a number of 
different coat colors were bred as pets. At the beginning of the 20th century, after 
the rediscovery of Mendelian genetics in plants, the next question was if the law 
of inheritance also applied to the other organisms. Mendelian ratios for the 
inheritance of different mouse coat colors were demonstrated by Cuenot in 1902, 
who then discovered the first embryonic lethal mutation in mammals through 
segregation studies in mice with a completely yellow coat. These mice are now 
known to carry a dominant regulatory mutation (lethal yellow, Ay) in the agouti 
gene. During this period, the first case of multiple alleles at the agouti gene was 
also described by Cuenot [6, 7]. 
 
 To date, 85 different alleles of the nonagouti locus have been identified, as 
reported in the Mouse Genome Informatics (MGI) database 
(http://www.informatics.jax.org). Recessive mutant alleles of the agouti gene 
are associated with the underproduction of phaeomelanin, which results in an 
increase in the presence of black pigmentation. Dominant mutations in the agouti 
gene affect the regulation of wild-type agouti expression, causing high levels of 
expression in all tissues of the body. Ectopic over-expression of the wild-type 
gene product in all tissues results in yellow-haired mice that are obese, diabetic 
and have increased susceptibility to hyperplasia, and spontaneous and 
chemically induced tumors ([8, 9], reviewed in [10-19]). Tumor susceptibility has 
been observed in a wide variety of tissues including the skin [20, 21], liver [22-
28], lung [23, 27], mammary gland [22, 23, 29-31] and urinary bladder [32]. 
Cloning of the agouti gene and identification of its protein product led to 
significant advances in characterization of the molecular mechanisms of wild-
type mouse coat pigmentation, obesity and diabetes [1, 2, 13, 33]. An historical 
perspective on the agouti gene can be found in the review by Wolff in 2003 [12].   
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Molecular Characterization of the Agouti Gene 
 
Agouti Gene Structure 
 
 In 1992, the agouti gene was cloned by Bultman et al. utilizing the 
radiation induced inversion mutation, Is(17; In2)1Gso. The limb deformity (Fmn1, 
previously known as ld) and nonagouti (a) loci are normally separated by 22 cM 
on mouse chromosome 2. In mice carrying the Is(17;In2)1Gso mutation, an 
interstitial inversion in chromosome 2 with breakpoints in a and Fmn1 resulted in 
the juxtaposition of Fmn1 and a [34]. Probes for the previously cloned Fmn1 gene 
gave molecular access to the a locus, and the cloning and characterization of the 
agouti gene and protein structure [1]. 
 
 Agouti is a seven exon gene, which spans over a 165-kb distance on mouse 
chromosome 2 (Fig. 1) [35]. The first four exons of the agouti gene are part of the 
5’ untranslated region (UTR). Exons 5, 6 and 7 contain the protein coding 
sequences, which are 170 bp, 65 bp, and 385 bp long, respectively [1].  
 
 Alternative isoforms of agouti mRNAs contain different combinations of 
non-coding exons spliced to the same three coding exons (Fig. 1). Agouti gene 
expression is controlled by ventral-specific, and hair-cycle-specific promoters, 
which independently regulate the production of solid yellow hairs on the 
ventrum, or banded agouti hairs on the dorsum and ventrum, respectively. Two 
ventral-specific transcripts contain either exon 1, or exons 1 and 2, spliced to the 
three coding exons. These ventral-specific transcripts are expressed throughout 
the hair-follicle cycle in the ventrum and produce solid yellow hair coloration. 
Two hair-cycle-specific transcripts contain either exon 3 or exon 4 spliced to the
 5
Figure 1. Mouse agouti gene structure and alternative transcripts. The agouti gene structure is shown in the top 
panel, not drawn to scale. The four non-coding exons (1-4) are represented by parallelograms, and the three coding 
exons (5-7) are shown as block arrows. The length of each intron is indicated. Two ventral-specific transcripts 
contain either exon 1 (A) or exons 1 and 2 (B) spliced to the three coding exons, and they both specify solid yellow 
belly hairs in wild-type agouti mice. Two hair-cycle-specific transcripts contain either exon 3 (C) or exon 4 (D) 
spliced to the three coding exons, and they both specify the banded hairs on the dorsum and ventrum of wild-type 
agouti mice. Figure adapted from published literature [1, 36-38].  
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B) 
C) 
D) 
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three coding exons. These hair-cycle-specific transcripts are expressed between 
days 2-7 of the hair-follicle cycle in both dorsal and ventral skin and produce the 
sub-terminal band of yellow pigmentation in dorsal and ventral hairs [1, 37]. The 
regulatory regions of the agouti gene and the manner in which these different 
agouti promoters are activated are still unknown [12]. 
 
Agouti Protein Structure and Action 
 
 The mouse agouti protein is a 131-aa signaling peptide with a molecular 
weight of 14,341 Daltons. The agouti protein contains five domains; a signal 
sequence, mature N-terminus, basic domain, proline-rich region, and a cysteine-
rich carboxyl terminus (Fig. 2). 
 
 The hydrophobic N-terminus of the agouti protein contains a 22-aa 
putative signal sequence, which is essential for in vivo agouti signaling [39]. The 
mature N-terminus is 34-aa long and carries a conserved arginine. Glycosylation 
of this arginine is required for full biological activity of agouti protein in vivo [40]. 
The central basic domain (29 aa) has a high proportion of arginine and lysine 
residues, and is important for the efficiency of agouti signaling [40, 41]. A 
polyproline stretch lies between the basic domain and the cysteine-rich C 
terminus. In vitro studies showed that the contribution of the proline-rich region 
to agouti protein activity is minimal, and suggested that it might be important in 
forming the tertiary structure of the protein by acting as a flexible hinge between 
the C-terminus and the N-terminus of the protein [40, 42]. At the C-terminus of 
the agouti protein are 10 cysteine residues within the last 40 amino acids, which 
form 5 disulfide bonds. This cysteine–rich domain is required for melanocortin 
receptor binding, and can antagonize the binding of α-MSH to the melanocortin 
receptors in vitro [43, 44].  
 8
Figure 2. Agouti protein sequence and domain structure. The nonagouti protein has five different domains. The 
signal peptide sequence consists of the first 22 amino acids, highlighted in aqua color. The next 34 amino acids, 
presented in magenta color, form the mature N-terminus. The basic domain, which is highlighted with green, 
contains 29 amino acids. The 6 amino acids highlighted in grey constitute the proline-rich region. The yellow color-
coded area is the cysteine-rich region that has 10 cysteine residues out of a total 40 amino acids. Proline residues 
and cysteine residues are shown in green and red color, respectively. Figure adapted from published literature [1, 
2]. 
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Parallel to the changes in gene expression, agouti protein is highly 
expressed during the early stage of the hair-follicle cycle, as shown by 
immunohistochemistry studies [4]. Agouti protein is localized to the outer root 
sheath of the hair follicle and functions in the microenvironment of the hair 
follicle [4, 45] in a paracrine fashion [3]. 
 
 Agouti’s paracrine action was first noted by parabiosis experiments. 
Parabiotic union, where two animals are sharing blood circulation, has been used 
to study the interrelationships of the endocrine glands between the agouti 
mutants, lethal yellow (Ay/a), and their nonagouti (a/a) littermates. Comparison 
of the rate of body-weight gain between parabiotic pairs of Ay/a and a/a mice 
throughout the experiment showed that there were no effects of parabiosis on 
the rate of weight gain of either animal. This observation suggested that agouti 
protein acted in a localized manner to induce obesity, and not by entering into 
the general circulation [46].  
 
 Skin transplantation experiments by Silvers and Russell [45, 47-50] 
indicated that the primary site of action of the agouti protein is the follicular 
microenvironment, and that the agouti protein acts in a cell non-autonomous 
manner. Transplantation of non-pigmented but genetically yellow embryonic 
skin to newborn mice with black hair color resulted in intense yellow 
pigmentation of hair around the edges of the skin graft, demonstrating that host 
melanocytes migrate into the graft follicles and produce pigment according to 
the follicular genotype of the graft, independent from their own genotype. In 
other words, paracrine action of agouti protein expressed from follicular cells of 
graft tissue was regulating the melanogenesis in the host melanocytes. 
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 Further research with keratin-agouti-SV40 (KAS) transgenic mice 
designed to understand the regulation of pigmentation patterning also 
supported the findings of the skin transplantation experiments, showing 
paracrine action of agouti protein [3]. In KAS transgenic mice, agouti expression 
is directed to basal cells of the epidermis, which are the non-pigmented cells at 
the bottom layer of the epidermis that give rise to the epithelial keratinocytes. 
Stripes of yellow pigmentation are observed in KAS transgenic mice, which 
corresponded to patches of basal epidermal cells expressing agouti. This study 
demonstrated the limited radius of agouti protein action, and supported the 
previous studies suggesting paracrine action of agouti protein.  
 
 Orthologs of the mouse agouti gene have been isolated in different 
species, including B. taurus (cattle) [51], C. familiaris (dog) [52], H. sapiens (human) 
[53], R. norvegicus (rat) [54], and S. scrofa (pig) [55]. The agouti proteins are highly 
conserved in these species. The rat and mouse agouti proteins are 93% identical 
at the amino acid level. The pig, dog, human and cattle proteins are 81%, 80%, 
78% and 77% identical to the mouse agouti protein, respectively.  
 
Agouti Mutants 
 
 Agouti mutant mice exhibit a wide range of coat color phenotypes as a 
result of different mutations that impact agouti regulation or protein structure.  
All the different alleles of the nonagouti locus represent an intricate dominance 
hierarchy of coat color [36, 50, 56, 57]. Hair pigmentation changes from solid 
yellow, as observed in mice carrying the most dominant alleles, to solid black in 
mice with the most recessive mutations.  
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 At the top of the dominance hierarchy is the lethal yellow (Ay) allele. 
Lethal yellow mice have a regulatory mutation that causes constitutive over-
expression of the wild-type agouti gene product in all tissues in heterozygous 
animals, including the skin, which results in full yellow coat coloration over all 
of the body. Black-and-tan (at) and nonagouti (a) are two examples of recessive 
mutations at the nonagouti locus. An insertion in the nonagouti locus in black-
and-tan (at/at) mice has a negative impact on expression of the hair-cycle-specific 
transcripts that make banded hairs, but does not affect expression of the ventral-
specific transcripts that make solid yellow hairs. Therefore, black-and-tan mice 
have completely black hair on the dorsum and completely yellow hair on the 
ventrum [37]. Nonagouti (a) has a pigmentation pattern that is very close to 
being a null mutation. Nonagouti mice are predominantly black, except for small 
amounts of phaeomelanin around the pinnae, nipples, and perineum [50]. In 
mice carrying the nonagouti allele, an insertion in the locus blocks most all 
expression of the hair-cycle-specific and ventral-specific transcripts [1]. At the 
bottom of the hierarchical series are mice carrying the extreme nonagouti (ae) 
allele, which have a completely black coat color resulting from a complete loss of 
agouti function [58]. 
 
Dominant Regulatory Mutations of Agouti 
 
 Six dominant regulatory mutations — lethal yellow (Ay), viable yellow 
(Avy), intracisternal A particle yellow (Aiapy), intermediate yellow (Aiy), sienna 
yellow (Asy), and hypervariable yellow (Ahvy) — all exhibit yellow coat coloration 
due to continuous action of the agouti protein in the skin. 
 
The lethal yellow (Ay) mutation is the result of a 120-170 kb deletion of the 
coding region of the ubiquitously expressed hnRNP associated with lethal 
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yellow (Raly) gene, which places agouti under the regulatory control of the Raly 
promoter [9, 59]. Under the transcriptional control of the Raly promoter, the 
agouti gene is ubiquitously over-expressed in Ay mutants [8]. Animals 
homozygous for the Ay mutation die during embryogenesis due to the deletion 
of the Raly gene [9, 59]. Heterozygotes for the Ay mutation have yellow coat 
color, and exhibit the pleiotropic effects of obesity, diabetes, and cancer as a 
result of the ectopic over-expression of the wild-type agouti protein [8]. 
 
The five non-lethal dominant regulatory mutations — Avy, Aiapy, Aiy, Ahvy, 
and Asy — are the result of insertions into the non-coding regions of the 
nonagouti locus. Expect for Asy, these dominant mutations are caused by 
insertions of an intracisternal A particle (IAP) into the locus, which changes the 
regulation of agouti expression [60-63]. Regulatory sequences within one of the 
long terminal repeats of the IAP elements constitutively activate the agouti gene, 
much like the Raly promoter in the Ay allele, and results in ubiquitous over-
expression of the agouti protein in all cell types throughout the body. A similar 
situation exists for the Asy mutation, wherein a novel element is inserted to the 
locus, instead of an IAP.  
 
 The pleiotropic effects associated with ubiquitous over-expression of 
agouti have been called the ‘Yellow Obese Mouse Syndrome’ [50], where the 
main characteristics of the syndrome include yellow coat color, obesity, 
hyperinsulinemia, increase somatic growth, and tumor susceptibility (reviewed 
in [11, 15, 38, 64]). The full spectrum of the yellow obese mouse syndrome can be 
observed in mice carrying the two dominant regulatory mutations Ay and Avy. 
Obesity, hyperinsulinemia, and increased somatic growth have also been 
demonstrated for mice carrying the mutations Aiy, Asy, Ahvy, and Aiapy. It is highly 
likely that mice carrying these mutations also have an increased susceptibility to 
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tumorigenesis, but this has not yet been investigated for these mice. In mice 
carrying dominant agouti mutations, increasing levels of agouti expression are 
associated with the amount and intensity of phaeomelanin (yellow pigment) in 
the coat and with the degree of obesity [63, 65]. Additionally, studies with 
transgenic mice that ubiquitously express the normal agouti protein throughout 
their body demonstrated that ectopic agouti expression is sufficient to 
recapitulate the obesity, diabetes, and yellow coat color phenotypes observed in 
mice with these spontaneous dominant agouti mutations [33].  
 
Regulation of Pigmentation by Agouti Signaling 
 
 Melanocytes switch from eumelanin to phaeomelanin pigment production 
depending on the presence of the α-MSH or agouti proteins within their 
follicular environment. α-MSH and agouti compete for the binding of MC1R on 
melanocytes with similar levels of affinity (Kd 2.3 nmol/l and Kd 3.7 nmol/l, 
respectively) [66, 67]. α-MSH activates adenylyl cylase through MC1R, which 
increases cyclic adenosine monophosphate (cAMP) synthesis. This is followed by 
an increase in tyrosinase synthesis, which triggers eumelanin pigment 
production (reviewed in [12, 68]). Agouti is transiently expressed during the 
early stages of each hair-follicle cycle and regulates the switch from eumelanin to 
phaeomelanin pigment production.  When agouti binds to the MC1R, it displaces 
or excludes the binding of α-MSH, and thus prevents adenylyl cylase activation 
and cAMP production [5]. In response to reduced cAMP levels, tyrosinase 
synthesis decreases and eumelanin pigment production is switched to 
phaeomelanin production (reviewed in [12, 68, 69]). Agouti signaling has been 
shown to down-regulate transcription of eumelanogenic genes such as 
tyrosinase-related protein 1 (Tyrp1), dopachrome tautomerase (Dct), and 
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tyrosinase (Tyr) [70, 71]. Additionally, up-regulation of three genes, 
minichromosome maintenance deficient 6 (Mcm6), transcription factor 4 (Tcf4), 
and an unknown retinal gene, have been shown during phaeomelanogenesis 
[72].  
 
Molecular Mechanisms of Obesity and Diabetes in Yellow 
Mice  
 
 Ubiquitous over-expression of agouti is responsible for the pleiotropic 
effects observed in mice carrying dominant agouti alleles. Confirmation of the 
association between agouti protein expression, obesity, and diabetes was first 
demonstrated by ectopic expression of the wild-type agouti gene under the 
ubiquitously expressed β-actin promoter in transgenic mice [14, 33].  
 
 Melanocortin receptors are seven-transmembrane G protein-coupled 
receptors (GPCR) that respond to α-MSH and adrenal corticotropic hormone 
(ACTH) stimuli [73]. All five members of the melanocortin receptor family 
(MC1R through MC5R) differ in their tissue distribution, physiological roles, and 
ligand affinity (reviewed in [74, 75]). MC1R is expressed in the skin in 
melanocytes and keratinocytes, and regulates coat color pigmentation. It binds to 
α-MSH with the highest affinity, which is followed by adrenocorticotropic 
hormone (ACTH), and β-MSH. MC2R, which is expressed by the adrenal cortex 
and adipocytes, only responds to ACTH, and induces adrenocortical 
steroidogenesis [76, 77]. MC3R and MC4R are widely expressed in the brain, and 
participate in the hypothalamic regulation of food intake and body weight. 
MC4R loss of function is associated with severe early onset obesity in humans. 
Both MC3R and MC4R are activated by α-MSH, β-MSH and ACTH, and MC3R 
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also binds to γ-MSH (reviewed in [78, 79]). MC5R is ubiquitously expressed in 
peripheral tissues and sebaceous glands, and activated by α-MSH, β-MSH, and 
ACTH signaling. Recently, MC5R has been shown to act in regulation of exocrine 
gland function and human sebocyte differentiation [80]. 
 
  Ectopic expression of agouti in the brain is primarily responsible for the 
obesity and diabetes phenotypes in lethal yellow (Ay) and viable yellow (Avy) 
mice. Transgenic studies with Mc3r and Mc4r knockout mice, which exhibit a 
similar phenotype to “yellow obese mice” with regard to weight gain and 
diabetes, pointed out the possible interaction between central melanocortin 
receptors and agouti protein [81, 82]. Pharmacological studies showed that 
agouti antagonizes MC3R and MC4R in the brain ([83], reviewed in [79, 84]), as it 
does MC1R in the skin of wild-type mice, resulting in altered feeding behavior 
and body weight. 
 
 Agouti action on adipocytes is also associated with obesity and diabetes, 
independent of its action through MC3R and MC4R in the hypothalamus. 
Paracrine/autocrine action of agouti in adipose tissue has been suggested to 
contribute to the obesity phenotype in yellow mice [13, 85, 86]. Fatty acid binding 
protein 4, adipocyte (Fabp4)-agouti transgenic mice, which express agouti only in 
adipocytes, had significantly heavier body weights even though the regulation of 
food intake by the hypothalamus was intact [87]. Transgenic studies with Fabp4-
agouti mice demonstrated that agouti regulates adipogenesis, and proliferation 
and differentiation of preadipocytes through melanocortin receptors in the 
adipose tissue [88]. These findings suggested that weight gain and adipogenesis 
are coordinately regulated by melanocortin signaling in the hypothalamus and 
adipose tissue [87-90]. 
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  In humans the agouti gene is normally expressed in adipose tissue [53], 
and agouti mRNA levels are significantly elevated in adipose tissue of patients 
with type 2 diabetes [88]. Agouti signaling in adipose tissue has been shown to 
interact with insulin and induce obesity by up-regulating lipogenesis [90], and 
agouti synergistically works with insulin to increase fatty acid synthetase (FASN) 
activity [91]. Agouti has been shown to increase Fasn mRNA levels through an 
agouti responsive element, which is a novel sequence located in the Fasn 
promoter region [91]. Additionally, agouti is known to increase leptin (Lep) 
expression, synthesis, and secretion in adipose tissue, independent of 
melanocortin receptor antagonism [92]. 
 
 Agouti protein has been shown to increase intracellular calcium levels in 
certain cells in vitro, including adipocytes [89, 93, 94]. In both mouse and human 
adipocytes, agouti regulates lipogenesis and lipolysis partially through an 
intracellular calcium dependent mechanism [85, 95, 96]. Agouti treatment 
increases Fasn activity and mRNA levels, and increases triglyceride accumulation 
in 3T3-L1 adipocytes, which is inhibited by Ca2+ channel blockade [95]. 
Treatment of yellow obese Avy/a mice with the calcium channel blocker, 
Nifedipine, resulted in significant decrease in fat pad weights and FASN activity 
[96].  
 
 In adipocytes, in addition to the regulation of Fasn and Lep gene 
expression, agouti also directly regulates expression of signal transducer and 
activator of transcription 1 (Stat1) and Stat3, and peroxisome proliferator 
activated receptor gamma (Pparg) [97].  Increased expression levels of Stat1, 
Stat3, and Pparg was first observed in Fabp4-agouti transgenic mice, and similar 
increases were observed in 3T3-L1 adipocyte cultures treated with agouti protein 
[97]. Agouti has been suggested to regulate Pparg expression through 
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melanocortin signaling, as treatment of 3T3-L1 adipocytes with α-MSH has been 
shown to block the effects of agouti on Pparg expression [87]. However, the 
molecular mechanisms that underlie the regulation of Stat1 and Stat3 by agouti 
are still under investigation.  
 
AGOUTI SIGNALING IN TUMOR PROMOTION 
 
 The association between the agouti gene and susceptibility to tumor 
formation has been recognized since the identification of yellow mice (reviewed 
in [10-19]). Recently, transgenic experiments confirmed the role of agouti as a 
tumor promoter, and demonstrated that it promotes tumorigenesis in the 
absence of obesity and diabetes [98, 99]. In order to understand the context and 
significance of current knowledge of agouti signaling during tumor promotion, 
background information on the following processes will be presented: two-stage 
skin carcinogenesis model, tumor susceptibly in mouse skin, and the increased 
susceptibility of mouse skin to tumorigenesis during the anagen stage of the hair-
follicle cycle. 
 
Two-Stage Model of Skin Carcinogenesis 
 
 
 Skin cancer is the most common form of cancer in humans. Every year 
over one million new patients are diagnosed with skin cancer [100]. Skin acts as a 
protective barrier against different environmental conditions, such as ultraviolet 
radiation (UV), injury, infectious agents, and chemicals, which are known risk 
factors for skin cancer. Although the main risk factor of skin cancer is the 
exposure to artificial or natural UV, others factors like human papillomavirus 
infections or exposure to chemicals like arsenic can cause development of cancers 
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in the skin. Additionally, certain hereditary conditions can increase the tendency 
to develop skin cancer [101, 102]. Depending on the underlying cause, different 
cell types in the epidermal layer of the skin are affected and the origin of the 
tumor cells determines the characteristics of the skin cancer. The most common 
form of skin cancer is basal cell carcinoma (BCC), which originates from the 
round basal cells located in the lower layer of the epidermis. Melanomas are the 
leading cause of death due to skin cancer, and originate from pigment producing 
cells, melanocytes. Squamous cells at the upper epidermal layer give rise to 
squamous cell carcinomas (SCC). Additionally, precancerous conditions such as 
follicular papillomas, actinic keratosis, and Bowen’s disease can turn into 
squamous cell carcinomas [103].  
 
 Skin cancer can be recapitulated in mice in a two-stage carcinogenesis 
model. These experiments on mouse skin have shown that transformation of 
normal cells requires at least two separate events, initiation and promotion, 
which are then followed by tumor progression [104-109] (Fig. 3).  
 
The first step in tumorigenesis is initiation, which is a single, irreversible, 
mutagenic event, and precedes tumor promotion. The polycyclic aromatic 
hydrocarbon, 7,12-dimethylbenz[a]anthracene (DMBA), is frequently used as an 
initiating agent in skin carcinogenesis experiments. A single application of 
DMBA to the skin causes mutations in the Harvey rat sarcoma virus oncogene 1 
(Hras1) gene, which is frequently observed in papillomas and SCC [110]. After 
initiation with DMBA, promotion of the skin with physical, chemical, or 
biological agents is required for clonal expansion of the initiated cell that carries  
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Figure 3. Two-stage model of carcinogenesis. Possible outcomes in a two-stage 
carcinogenesis experiment. (A) Tumors develop following a one-time initiation 
event and repeated exposure of initiated cells to a tumor promoter. Either tumor 
initiation (B) or tumor promotion (C) alone is inadequate to induce the 
development of tumors. 
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a non-lethal mutation. Tumor promoters may be external or internal stimuli. 
Repeated exposure of the skin to promoting agents in short intervals results in 
altered gene expression and affects cell growth and differentiation of the initiated 
cells. During tumor promotion, a continuous mitogenic stimulus provides a 
growth advantage to the initiated cells by either increasing resistance to 
differentiation or apoptosis or increasing proliferation rates [111]. Promotion is 
an essential step for tumor development, which is rate-limiting and reversible; 
thus, therapeutic interventions focused on the prevention and regression of 
tumor promotion are very likely to be effective [109, 112-114]. 
 
 The two-stage skin carcinogenesis model has allowed investigators to 
explain the complex biological events behind carcinogenesis in simple terms, and 
has been an essential tool to study the tumorigenesis process in mice and 
humans. Discoveries about tumor initiation and promotion made in two-stage 
skin carcinogenesis experiments are also relevant to other tissues [115]. These 
experiments are widely used to elucidate the role of chemical carcinogens or 
oncogenes, which can be established according to the experimental conditions 
required for a carcinogen to drive tumor development (Fig. 3). Tumor initiators 
are expected to give rise to skin tumors after a single application of the agent to 
the skin of mice, when followed by multiple applications of a tumor promoter to 
the skin, such as 12-O-tetradecanoylphorbol-13-acetate (TPA).  Likewise, agents 
can be tested for their ability to act as tumor promoters by first initiating the skin 
with DMBA, followed by repeated applications of the agent in question to the 
skin and then monitoring the skin of mice for the development of skin tumors 
over time.  
 
 Much of our information about tumor development in mice and humans 
was based on research using the two-stage skin carcinogenesis model. Following 
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advancements in the understanding of skin carcinogenesis, this model has also 
been used to study tumor development in other tissues, such as the liver, lung 
and breast. Recapitulating these different types of tumors allowed investigators 
to understand biological changes associated with different stages of tumor 
development. 
 
Tumor Susceptibility in Mouse Skin 
 
 Due to the differences in their genetic background, the degree of 
susceptibility to tumorigenesis varies between inbred mouse strains [105, 116]. 
Inherited traits that cause initiation or promotion of the normal cells increase the 
susceptibility to tumorigenesis, as cells have already gone through one of the two 
essential steps required for tumor development (Fig. 3).  
 
 The v-Ha-ras transgenic TG.AC mouse line is one of the examples that 
demonstrate the relationship between inherited factors and susceptibility to 
carcinogenesis. In this transgenic model, increased susceptibility to skin 
carcinogenesis is observed as they carry an activated allele of the Hras1 
oncogene, which is a frequently observed mutation in initiated skin cells [117]. 
SENCAR, sensitivity to cancer, is another well-known mouse model that was 
bred for their increased susceptibility to tumor development. SENCAR mice 
show high susceptibility to initiation and promotion in two-stage carcinogenesis 
experiments, as they require lower doses of carcinogens, and develop higher 
numbers of tumors in a shorter time compared to other inbred mice [107, 118]. 
Although the molecular basis of tumor susceptibility in SENCAR mice is 
unknown, involvement of multiple genes has been suggested as different strains 
of SENCAR mice show variability in susceptibility to tumorigenesis [112, 119]. 
The tumor promotion stage has been observed as the key event that determines 
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the degree of tumor susceptibility in different inbred mouse strains [116]. 
Carcinogenesis studies with SENCAR mice have supported previous 
observations, indicating the correlation between the promotion stage and degree 
of tumor susceptibility [112]. 
  
 Inbred mouse strains that demonstrate different degrees of tumor 
susceptibility have been utilized for quantitative trait analysis, and currently 17 
quantitative trait loci (QTL) have been localized for tumor susceptibility in skin:  
skin tumor susceptibility (Skts1 through Skts13) (reviewed in [120]), and 
promotion susceptibility (Psl1 through Psl4) loci [121, 122]. Identification of new 
genetic mechanisms that impact tumor susceptibility will be facilitated by 
cloning and characterizing the genes associated with these QTLs.  
 
Hair-Follicle Cycle and Tumor Susceptibility  
 
 The hair follicle (HF) is a regenerating structure that resides in the dermal 
layer of the skin (Fig. 4). All mature hair follicles proceed through cyclical 
changes throughout the life of mammals, which can be categorized into four 
phases; growth (anagen), regression (catagen), relative resting (telogen), and 
shedding (exogen). Hair follicles exhibit distinct morphological characteristics at 
each stage, which is helpful for identification and dissection of anagen, catagen, 
and telogen stages [123]. 
 
 The most recognizable structure of the HF is the hair bulb, which is an 
onion shaped structure formed by relatively undifferentiated matrix cells and HF 
melanocytes. The dermal papilla (DP) consists of differentiated mesenchymal 
cells, and resides adjacent to the hair bulb at the base of the HF, which is later  
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Figure 4. Structure of the hair follicle and the hair-follicle cycle stages. 
Morphological changes associated with different hair-follicle cycle stages are 
presented. The stages of the hair-follicle cycle are anagen (growth), catagen 
(regression), and telogen (resting). The structures of an anagen hair follicle are 
shown: hair shaft (HS), sebaceous gland (SG), inner root sheath (IRS), outer root 
sheath (ORS), matrix (MX), and dermal papilla (DP). The hair follicle exhibits 
distinctive morphology associated with each stage (see text for details). Figure 
adapted from published literature [123]. 
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surrounded by the hair bulb during the anagen stage of the hair-follicle cycle.  
DP cells orchestrate hair follicle formation during embryogenesis, and the hair 
bulb continues to be an important structure during hair-follicle cycling and in 
hair formation in postnatal life. Matrix cells (MX) of the hair bulb differentiate    
into the hair shaft (HS) and inner root sheath (IRS), which surrounds the HS. The 
outer root sheath (ORS) consists of HF keratinocytes, which form the outermost 
layer of the HF, merging the basal layer of the epidermis and the HF. The bulge 
region is a specialized part of the ORS located at the insertion site of the arrector 
pili muscle (APM), which contains stem cells that give rise to both the HF and 
interfollicular keratinocytes. 
 
  Anagen is the stage of active growth, when the hair follicle proliferates 
and differentiates to produce a new hair shaft. The first set of changes marking 
the start of anagen is the enlargement and repositioning of the DP inside the hair 
bulb. After receiving initiation signals from the hair matrix, DP cells signal back 
to the MX, instructing the matrix cells to differentiate and proliferate to form a 
new hair shaft. During anagen, melanin pigment is synthesized by hair follicle 
melanocytes. The hair follicle, which is located in the dermis, elongates and 
crosses the dermis-subcutis border, growing deep into the subcutis. Additionally, 
epidermal and dermal layers of the skin thicken to accommodate the growing 
hair follicle [124-127]. 
 
 Apoptotic events control the regression of the hair follicle throughout the 
catagen stage, which is a transitional stage between anagen and telogen. During 
catagen, the DP condenses and resumes its ball-shape, while the hair bulb 
retracts back toward the dermis, leaving the DP outside of the bulb. As the HF 
gets shorter, all the HF structures move back into the dermis leaving behind a 
membrane trail. At the end of catagen, the hair follicle reaches its smallest size 
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before entering into the next resting period [124-127]. By the start of telogen, 
molecular pathways that have regulated the changes during anagen and catagen 
turn back to their basal activity levels. Throughout telogen, the hair follicle 
preserves its size and shape, and the hair shaft stays attached to the follicle until 
it is shed or pushed out by the new hair produced during the following anagen 
stage [124-127]. 
 
 Initiation of the hair-follicle cycle, progression through each of the stages, 
and the transitions from one stage to the next requires the involvement of 
different signaling pathways communicating mostly between matrix cells of the 
hair bulb and the DP. These molecular controls and changes associated with each 
stage of the hair-follicle cycle are less clear than the associated morphological 
changes. Many signaling pathways that are important in embryonic 
development, such as hedgehog, patched, Wnt, dishevelled, armadillo, 
engrailed, and Notch are critical for normal hair follicle morphogenesis [124], 
and also regulate postnatal hair follicle growth and cycling processes [127]. For 
instance, transient expression of sonic hedgehog signaling (Shh) is required for 
the embryonic development of the hair follicle, and it also acts as a biological 
switch initiating the anagen stage in cycling postnatal follicles [128]. 
Additionally, estrogens, thyroid hormones, glucocorticoids, retinoids, and 
growth hormones modulate hair growth [124], and many genes, including a, 
Pdgfa, Stat3, and Prl act as molecular mediators of hair follicle growth [126]. 
Integration of bone morphogenetic protein (Bmp) and Wnt signaling pathways 
has been suggested to regulate hair follicle stem cell differentiation and 
proliferation [129], along with other recently identified regulators, such as 
telomerase reverse transcriptase (Tert) [130, 131] and RAS-related C3 botulinum 
substrate 1 (Rac1) [132]. The molecular mechanisms that control hair follicle 
morphogenesis and cycling have been shown to be involved in the regulation of 
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embryonic and postnatal development of other tissues, such as teeth, feathers, 
and mammary glands [133], and are suggested to have a role in other 
developmental systems [127]. Details of the molecular mechanisms underlying 
the hair-follicle cycle and its regulation have been reviewed by Stenn and Paus 
[126, 134].   
 
 The first two hair-growth cycles (catagen, telogen, anagen) after birth are 
completed precisely in 12 weeks. The first catagen stage takes place during the 
first two weeks of life, followed by the first telogen and anagen stages, which are 
completed in three and a half weeks after birth. The second postnatal hair-follicle 
cycle takes twice as much time to complete, and occurs during the second and 
third months after birth. All postnatal hair follicles go through the first and 
second hair-follicle cycles in a synchronized manner. After the second anagen 
stage this synchronization is lost and each hair follicle starts to cycle independent 
from one another, so in one skin section follicles in all different hair-follicle cycle 
stages can be observed [125]. In adult mice, the hair-follicle cycle can also be 
synchronized under defined experimental conditions. If hair shafts are removed 
by hot wax application during the second telogen stage, at around 7 to 8 weeks 
of life, the second anagen stage will be initiated at the same time for all the hair 
follicles in the epilated area. As all the hair follicles are induced to initiate anagen 
at the same time immediately following epilation, they progress synchronously 
through the next anagen, catagen and telogen stages. Synchronization of the hair-
follicle cycle allows one to study histological and molecular changes during each 
specific stage of the hair cycle [135]. 
 
Besides hair shaft formation, the hair-follicle cycle is important at the 
cellular level as it impacts different molecular events, such as cell-cell 
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communication, tissue regeneration, aging, and carcinogenesis (reviewed in 
[126]). 
 
 Different cell types of the hair follicle give rise to morphologically distinct 
tumors, and an association between different types of tumors and specific stages 
of the hair-follicle cycle has been known for many decades [136-138]. A 
systematic study was conducted in which the histology of various types of hair-
follicle tumors was correlated with the stage of the hair-follicle cycle when 
tumors arose [131]. This study demonstrated that tumors that arise in anagen 
originate from the hair MX, ORS and IRS of the hair follicle, which form the hair 
shaft of the mature anagen follicle [139]. Additionally, it has been demonstrated 
that a majority (88%) of hair-follicle tumors develop during the anagen phase 
from the fully differentiated follicular cells [139]. Skin papillomas have been 
shown to originate from hair follicle structures in v-Ha-ras transgenic TG.AC 
mice after initiation of the anagen stage [140]. Two-stage carcinogenesis 
experiments demonstrated that the sensitivity of the skin to tumor formation is 
greatest during the anagen stage of the hair-follicle cycle [137, 141]. Both Swiss 
and SENCAR mice developed higher numbers of tumors at the end of the 40-
week period following initiation by DMBA during the early anagen stage of the 
hair-follicle cycle. 
 
 These observations have been supported by the demonstration of the 
transient proliferation of follicular epithelial stem cells during early anagen [142]. 
All stem cells are especially susceptible to tumorigenesis due to their potential 
for proliferation and their long-term presence in tissues, which allow for the 
accumulation of multiple oncogenic events in one cell. Follicular epithelial stem 
cells located in the bulge region of the ORS give rise to both the hair shaft and 
epidermis (reviewed in [143, 144]), where the skin papillomas and other anagen 
  29
tumors have been shown to originate. It has been suggested that stimulation of 
follicular epithelial stem cells by the initiation of the anagen stage is responsible 
for increased susceptibility to tumorigenesis in mouse skin during the anagen 
stage of the hair-follicle cycle [142].  
 
Agouti is a Tumor Promoter 
 
 Even though many aspects of the molecular mechanisms of agouti-
induced obesity and diabetes have been explained, virtually nothing is known 
about the molecular basis of agouti-induced tumor susceptibility in yellow mice. 
 
 The dominant agouti mutations Ay and Avy influence tumor development 
by shortening the latency period (time from initial exposure to first detection) of 
tumor formation [28, 38] and increasing the prevalence of tumors (number of 
animals effected) [15, 26, 27, 98, 99]. While these typical effects of Ay and Avy 
mutations are observed in many tissues, several studies have revealed 
contradictory findings. First, there was no change in the latency period of 
chemically induced thymic lymphomas observed in mice carrying either the Ay 
or Avy mutations [145]. Additionally, a decreased prevalence of spontaneous 
teratomas [146] and mammary tumors have been reported in mice carrying Ay. 
Despite the decrease in number of animals with mammary tumors, the latency 
period needed for development of mammary tumors in Ay mice was still shorter 
[147]. There are also contradictory findings on the in vitro transformation of 
fibroblasts from Avy mice. A decreased prevalence of spontaneous and 
chemically-induced transformation of primary fibroblasts from an Avy/a mouse 
was observed [148], whereas established cell lines from Avy/a fibroblasts showed 
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an increased prevalence during spontaneous focus formation experiments 
compared to a/a control cell lines [149].  
 
 To date, many different mechanisms have been proposed to explain the 
role of agouti in increasing tumor susceptibility in mice, including increased 
proliferation of transformed cells, increased DNA and protein synthesis, 
increased mitosis in sensitive tissues, and metabolic changes in precancerous 
cells [15, 16, 38], but the role of agouti in tumor susceptibility remains largely 
unknown.  
 
 The first demonstration that agouti may have a role in tumor promotion 
independent of its effects on obesity and diabetes came from a study in Avy/a 
mice. Depending on the methylation level of regulatory elements of the IAP 
insertion in the Avy allele, Avy/a mice show different levels of agouti expression 
and different degrees of obesity and diabetes. High levels of IAP methylation 
result in extremely low levels of ubiquitous agouti expression in Avy/a mice. 
These mice have normal body weights and normal blood glucose levels, but they 
have a subtle alteration in coat color (slight increase in size of sub-terminal 
yellow band) that is called pseudoagouti. Low levels of IAP methylation result in 
high levels of ubiquitous agouti expression in Avy/a mice. These mice are obese, 
diabetic, and have a solid yellow coat color. Obese yellow Avy/a mice, lean 
pseudoagouti Avy/a mice, and lean black nonagouti a/a control mice were fed a 
diet containing lindane (gamma-hexachlorocyclohexane) for 24 months [27]. In 
response to lindane feeding, lean pseudoagouti Avy/a mice had a higher 
prevalence of lung tumors, and hepatocellular adenoma and carcinoma than lean 
a/a control mice, whereas the obese yellow Avy/a mice had the highest prevelance 
in all cases. It is unclear if the higher number of obese yellow Avy/a mice with 
tumors compared to lean pseudoagouti Avy/a mice was caused by metabolic 
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effects associated with obesity and diabetes, or to higher levels of ubiquitous 
agouti expression in the yellow mice. Importantly, the greater tumorigenic 
response of lean pseudoagouti Avy/a mice compared to lean nonagouti a/a mice 
demonstrated that obesity and tumor susceptibility are independent effects of 
ectopic agouti expression [27]. 
  
 A transgenic study in which the albumin promoter was used to direct the 
expression of the wild-type agouti cDNA to the liver demonstrated that agouti is 
a tumor promoter in the liver independent of its effects on obesity and diabetes. 
Albumin (Alb1)-agouti transgenic mice, in which agouti protein is ectopically 
expressed only in the liver, have normal body weight and normal levels of 
plasma insulin and blood glucose [98]. Diethylnitrosamine (DEN) is a mutagenic 
agent frequently used for the initiation of liver cells. A single intraperitoneal 
injection of DEN in alb-agouti transgenic mice and non-transgenic control mice 
resulted in an increased number of tumors that developed in the livers of the 
transgenic mice compared to controls. This single initiation event with a 
hepatocellular carcinogen was sufficient to lead to a significantly greater number 
of liver tumors in transgenic mice following continuous exposure of the initiated 
liver cells to high levels of agouti signaling. These findings demonstrated that 
agouti acts as a tumor promoter in a two-stage carcinogenesis experiment, and 
its tumor promoting action is independent from the obesity and diabetes 
phenotypes [98, 99].  
 
 A second transgenic study had the goal of extending these findings and 
defining more precisely the role of agouti in carcinogenesis. For this purpose, 
transgenic mice expressing the agouti gene in the skin under the regulatory 
control of the keratin complex 1, acidic, gene 14 (Krt1-14, abbreviated as K14) 
promoter were used in classical two-stage skin carcinogenesis experiments. K14-
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Agouti mice over-express the agouti gene in the skin in a constitutive manner, 
resulting in continuous antagonism of MC1R throughout the hair-follicle cycle 
and in mice with a solid yellow coat color. The K14-Agouti transgene is 
expressed in the basal layer of the epidermis and outer root sheath of the hair 
follicle. Similar to the liver-specific transgenic mice, K14-Agouti transgenic mice 
are not obese or diabetic, again demonstrating that agouti acts in a paracrine 
fashion within a few cell distances from its point of secretion, and not by entering 
into the general circulation [150] (Fig. 5).  
 
 K14-Agouti transgenic mice were used in a classical two-stage skin 
carcinogenesis experiment designed to determine if agouti acts as a tumor 
promoter in the skin independent of obesity and diabetes [99]. Two groups of 
transgenic and control mice were treated with either the tumor initiator DMBA, 
or the tumor promoter TPA, and the number of skin papillomas that developed 
in transgenic and control mice was determined for 52 weeks. In the first group, 
where the skin of transgenic and control mice was only initiated by a single 
topical application of DMBA, the number of mice with skin papillomas and the 
number of papillomas per mouse were significantly greater in the transgenic 
mice. These data showed that a high level of agouti protein was able to promote 
the development of skin tumors following initiation, independent from the 
obesity and diabetes phenotypes. In the second group, both transgenic and 
control mice were only promoted with repeated administration of the tumor 
promoter TPA, without any initiation. Neither the K14-Agouti transgenic mice 
nor the controls developed any papillomas during the 52 week period, indicating 
that agouti was not acting as an initiator, and that tumors do not arise 
spontaneously in K14-Agouti mice in the absence of initiation. 
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Figure 5. K14-Agouti transgenic and non-transgenic control mice. (A, B) 
Constitutive agouti signaling in the skin of K14-Agouti transgenic mice causes 
the mice to have a solid yellow coat color compared to their nonagouti (black) 
littermate controls. Transgenic mice are not obese or diabetic.  
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 In the same study, a third group of K14-Agouti transgenic and control 
mice were initiated with DMBA, which was then followed by TPA promotion. 
As expected, the control mice developed papillomas under these experimental 
conditions. In transgenic mice, K14-Agouti expression acted synergistically with 
the chemical tumor promoter, TPA, to increase the cumulative prevalence, 
multiplicity, and malignant conversion rate of tumors, and to decrease the latent 
period of tumor formation compared to control mice [99]. These two-stage 
carcinogenesis experiments with both alb-Agouti and K14-Agouti transgenic 
mice showed that agouti acts as a tumor promoter in the liver and skin, 
respectively, in the absence of the obesity and diabetes phenotypes. 
 
Although it has been clearly established that the agouti protein acts as a 
tumor promoter, the mechanism of action of agouti protein in tumor promotion 
is still unknown. We speculated that the constant presence of high levels of 
agouti protein (a paracrine signaling molecule) in the skin of K14-Agouti mice is 
the promoting force in these mice. As discussed above, the paracrine/autocrine 
action of agouti in the hypothalamus (in spontaneous dominant agouti mutants) 
and adipose tissue (in Fabp4-Agouti transgenic mice) was previously shown to 
be responsible for the obesity and diabetes phenotypes, rather than any systemic 
action of agouti protein. Additionally, agouti is known to directly regulate the 
expression of several genes functioning in pigmentation, lipogenesis, and 
adipocyte metabolism.  
 
In this research, the main goal was to extend these findings and to address 
the following fundamental issues regarding agouti and skin carcinogenesis: 
 
a) Identify the changes in gene expression patterns in the skin of K14-
Agouti transgenic mice using cDNA microarray and real-time quantitative 
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reverse transcriptase – polymerase chain reaction (qRT-PCR) analyses in 
order to identify molecular pathways associated with the promotion of 
skin carcinogenesis by the agouti protein.  
 
b) Determine if the over-expression of agouti in the skin of K14-Agouti 
transgenic mice is affecting the regulation and progression of the hair-
follicle cycle. 
 
 c) Investigate if changes in gene expression profiles in the skins of the 
transgenic mice are associated with specific stages in the hair-follicle cycle.  
 
 The agouti protein acts as a tumor promoter in the skin of K14-Agouti 
mice, as evidenced by the fact that skin tumors develop only following chemical 
initiation. In the untreated skin of K14-Agouti mice there is ongoing promotion 
due to the over-expression of agouti protein in the skin, but these mice do not 
develop skin tumors in the absence of initiation. Therefore, any gene expression 
changes detected in the untreated skin of K14-Agouti mice may be associated 
with the tumor promotion stage of skin carcinogenesis, and provide insight into 
the genetic pathways through which the agouti protein may be functioning in 
skin cancer. Differentially expressed genes in the skin of K14-Agouti transgenic 
mice are identified by microarray analysis, and the results of microarray analysis 
are validated and extended with qRT-PCR analysis.  
 
 Gene expression analysis using microarray technology can determine 
differential expression levels of thousands of genes simultaneously in a high-
throughput fashion. Microarray analysis has been a valuable tool for identifying 
changes in the expression of genes under different experimental circumstances, 
such as following a genetic alteration, during different stages of disease, or in 
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response to various treatments. The identification of split hand/foot 
malformation (ectrodactyly) type 1 (Shfm1) as a TPA responsive gene expressed 
in keratinocytes by microarray analysis is only one of many examples of the 
application of the microarray technique for novel gene discovery [151]. 
Additionally, microarray analysis can be utilized for establishing molecular 
signatures associated with different disease states for the purpose of diagnosis 
and for predicting disease outcome [152, 153]. In cancer research, microarray-
based techniques have been used in a wide range of applications, such as to 
identify biomarkers associated with different cancer stages, responses to therapy, 
and disease prognosis. In a recent study, microarray analysis was used to 
identify differentially expressed genes in mouse squamous skin cancer induced 
by DMBA and TPA treatment. Differential expression of four genes — annexin 
A1 (Anxa1), lipocalin 2 (Lcn2), S100 calcium binding protein A8 (calgranulin A) 
(S100a8), and serine/threonine kinase 38 like (Stk38l) — identified in mice were 
also shown to be differentially expressed in human skin tumor samples, 
demonstrating the strength of microarray analysis for the identification of novel 
cancer related genes [154]. 
 
 In the following chapter, the design and results of this study are 
presented. The non-initiated skins of K14-Agouti and control mice were 
examined by cDNA microarray analysis, resulting in the identification of 181 
genes that had significantly different expression levels in K14-Agouti mice 
compared to control mice. These gene expression changes are associated with the 
promotion stage of skin carcinogenesis in K14-Agouti mice. Constitutive 
signaling by agouti protein in the skin of K14-Agouti mice, independent of any 
effects of K14-Agouti on skin morphology or on timing of hair-follicle stages, 
caused these gene expression differences. Additionally, qRT-PCR analysis 
demonstrated that the levels and temporal patterns of expression of 10 genes 
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previously associated with skin and/or other epithelial cancers were 
significantly altered in the skin of K14-Agouti transgenic mice. Agouti-induced 
over-expression of these proto-oncogenes in the skin of K14-Agouti mice is 
proposed to be associated with their increased susceptibility to skin 
carcinogenesis. 
 
 In the last chapter, the results obtained from the microarray and qRT-PCR 
experiments are integrated into a hypothetical model to explain the mechanism 
of action of the agouti protein as a tumor promoter in skin carcinogenesis. 
Finally, strategies for future follow-on experiments to further investigate the role 
of agouti in tumor promotion and to test aspects of the proposed model are 
presented. 
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CHAPTER II 
 
DIFFERENTIAL EXPRESSION OF SKIN 
CANCER AND HAIR-FOLLICLE CYCLE 
REGULATED GENES IN TUMOR 
SUSCEPTIBLE K14-AGOUTI MICE 
 
 This chapter is a slightly revised version of a paper by the same title, 
which is ready for submission by Yesim Aydin-Son and Edward J. Michaud. 
 
 My use of “we” in this chapter refers to my co-author and myself. My 
primary contributions to this paper include: (1) identification, optimization and 
application of the experimental approaches, (2) some of the mouse husbandry, 
(3) tissue collections from mice, (4) most of the RNA isolation and cDNA 
preparation, (4) microarray experiments and analysis, and data mining, (5) most 
of the real-time qRT-PCR experiments, (6) interpretation of the qRT-PCR data, (7) 
hair-cycle synchronization experiments, (8) histological staging of the hair-follicle 
cycle, (9) most of the gathering and interpretation of literature, and (10) writing 
the manuscript. 
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INTRODUCTION 
 
 The mouse nonagouti (a) gene, hereafter referred to as agouti, encodes a 
paracrine-acting signaling molecule in the skin that regulates coat-color 
pigmentation [1, 2]. The agouti gene is expressed in the dermal papilla of hair 
follicles in a transient manner only during the early anagen (growth) stage of the 
hair-follicle cycle, when hair follicles proliferate and differentiate [3, 4]. Agouti 
signaling causes hair-follicle melanocytes to switch from black to yellow pigment 
production by signaling through the melanocortin 1 receptor (MC1R) [5]. As a 
result of this switch mechanism, individual hairs of wild-type mice have an 
agouti pigmentation pattern, which is black with a sub-apical yellow band [155]. 
Importantly, the skin of mice is also more susceptible to carcinogenesis during 
the anagen stage of the hair-follicle cycle [139, 141, 143], a time when many 
signaling pathways are normally activated in hair follicles (reviewed in [156-
158]). 
 
 Dominant regulatory mutations in the mouse agouti gene, such as lethal 
yellow (Ay) and viable yellow (Avy), cause ectopic over-expression of the wild-
type gene product in every tissue of the body [1, 2, 59]. This alteration in agouti 
expression results in yellow-haired mice that are obese, diabetic and have 
increased susceptibility to hyperplasia, and spontaneous and chemically induced 
neoplasia [8, 9] (reviewed in [11, 16, 17]) in a wide variety of tissues (e.g., skin 
[20, 21], liver [22-28], lung [23, 27], mammary gland [22, 23, 29-31], and urinary 
bladder [32]).  
 
 Liver-specific expression of the agouti gene in transgenic mice was shown 
to promote hepatocellular carcinogenesis, even in the absence of obesity and 
diabetes [98].  We recently extended these findings to show that expression of the 
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agouti gene in the skin of transgenic mice also promotes skin cancer in the 
absence of obesity and diabetes [99]. In K14-Agouti transgenic mice, the wild-
type agouti gene is over-expressed in the skin under the regulatory control of the 
keratin complex 1, acidic, gene 14 (Krt1-14, abbreviated as K14) promoter. These 
transgenic mice have yellow hair as a result of continuous agouti antagonism of 
MC1R on melanocytes, but do not exhibit the obesity or diabetes phenotypes 
observed in mice carrying the Ay or Avy mutations [150]. The obesity and diabetes 
phenotype exhibited by mice harboring the Ay and Avy mutations is likely caused 
by over-expression of agouti in the brain and antagonism of MC4R [83]. In two-
stage skin carcinogenesis experiments with K14-Agouti transgenic mice, the 
agouti protein was shown to act as a tumor promoter since it promoted the 
development of skin tumors only after the skin was initiated with a single sub-
carcinogenic dose of 7,12-dimethylbenz[a]anthracene (DMBA) [99]. Although 
agouti has been shown to promote the development of hyperplasia and 
neoplasia in numerous tissues, the mechanism of action of agouti protein in 
tumor promotion remains largely uncharacterized [12].   
 
 Our hypothesis for the role of the agouti protein in tumor promotion is 
that agouti may be inducing the up-regulation of proto-oncogenes as a 
consequence of high levels of constitutive paracrine signaling of cells and 
pathways that may or may not normally encounter agouti protein. As a first step 
to test this possibility, we used cDNA microarray and real-time qRT-PCR 
analyses in order to examine gene expression levels in the skin of non-initiated 
K14-Agouti transgenic mice compared to non-transgenic littermate control mice. 
Our goal was to identify changes in K14-Agouti skin at the molecular level due 
to over-expression of the agouti gene in the skin, which in turn could be 
associated with tumor promotion following spontaneous or chemical initiation. 
We identified a set of genes that are significantly up-regulated in the skin of K14-
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Agouti mice and that have previously been shown to play a role in skin, and 
epithelial cancer biology.  
 
MATERIAL and METHODS 
 
Mice 
 
 Mice of the transgenic line TG2579K14iA [150] were backcrossed to 
C57BL/6J mice for more than 10 generations in order to obtain transgenic mice 
that are congenic on the C57BL/6J genetic background, which are hereafter 
referred to as K14-Agouti transgenic mice. K14-Agouti transgenic mice are 
hemizygous for the transgene and are non-agouti (a/a) at the endogenous agouti 
locus, as determined by Southern blot analysis [1]. C57BL/6J (a/a) littermates 
were used as controls for K14-Agouti transgenic mice. All mice were maintained 
in the Mammalian Genetics Research Facility, Oak Ridge National Laboratory, 
Oak Ridge, TN, and all experiments involving mice were conducted under 
approved Institutional Animal Care and Use Committee protocols. 
 
RNA Isolation and cDNA Preparation 
 
 Dorsal skin sections from adult male K14-Agouti transgenic mice and a/a 
control mice were dissected and snap-frozen in liquid nitrogen. Total RNA was 
isolated using TRIzol (Invitrogen), followed by on-column DNAse treatment and 
a purification step with the Qiagen RNeasy Mini Kit. SuperScript II Reverse 
Transcriptase (Invitrogen Life Technologies) was used to generate cDNA 
according to the manufacturer’s instructions.  
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Microarray Analysis 
 
 Ontario Cancer Institute cDNA microarrays (OCI, Toronto, Canada) 
containing the NIA/NIH 15K mouse EST clone set [159] were used for 
microarray experiments. Labeling and hybridization of cDNAs were performed 
by following the TIGR Protocol for indirect amino-allyl labeling of cDNAs [160]. 
An optimized version of this protocol is available at 
http://web.utk.edu/~saydin/protocols. Three biological replicates were used to 
minimize experimental and individual variations. Total RNA from three 
different eight-week-old male K14-Agouti transgenic mice was hybridized 
individually against a pooled total RNA sample from three sex-matched, age-
matched non-agouti control mice. All three hybridizations were repeated with 
dye swapping to minimize dye bias in the microarray analysis. Since each one of 
the NIA 15K mouse ESTs is spotted in duplicate on the microarray slides, 12 data 
points were generated for the expression level of each gene, which were 
combined for statistical analysis. Fluorescence intensities were measured using 
ScanArray (GSI Lumonics), and Imagene 5.2 (BioDiscovery) was used for image 
acquisition and quantification. Composite images were generated by Imagene 
software. 
 
Statistical Analysis 
 
 BRB-ArrayTools developed by Dr. Richard Simon and Amy Peng Lam, 
and SAM (significance analysis of microarrays) [161] software packages were 
used for the statistical analysis of gene expression data. After local background 
correction with Imagene 5.2 output, average log (base 2) intensities were used for 
normalization. Each dye-swap experiment was individually normalized with 
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LOWESS analysis using BRB-ArrayTools software. Statistical significance of 
alterations in gene expression levels between transgenic and control mice were 
determined by SAM. Threshold values (delta) were selected by considering the 
total number of genes on the array, the number of genes found significantly 
different at that threshold value, and the False Discovery Rate (FDR) for the 
threshold. 
 
Real-Time qRT-PCR 
 
 The qRT-PCR method depends on the real-time measurement of PCR 
products amplified in every cycle, which is proportional to the amount of 
starting template [162-164]. We used the Cepheid SmartCycler real-time PCR 
machine for the qRT-PCR experiments. The TaqMan primers and probes were 
purchased from Applied Biosystems (TaqMan Assays-on-Demand Products 
Assay numbers: Mm00438337_m1, Mm00476174_m1, Mm00516876_m1, 
Mm00515219_s1, Mm00448100_m1, Mm00435540_m1, Mm00440911_m1, 
Mm00439518_m1, Mm00456961_m1, Mm00436931_m1). The 18S RNA (Rn18s) 
gene was used as an internal control to normalize experimental data. The 
threshold cycle (CT) for all experimental genes was first normalized to the 
corresponding Rn18s CT. Relative fold differences were then determined using 
the 2–∆∆CT method [165] by comparing each experimental sample to the control 
sample.  
 
Synchronization of Hair-Follicle Cycle 
 
 To repeat the qRT-PCR experiments on skin samples in which the exact 
stage of the hair-follicle cycle was determined by diagnostic histology, we 
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synchronized the hair-follicle cycle on the dorsal skin of eight-week-old female 
K14-Agouti transgenic and control mice by wax epilation, as described 
previously [166]. Mice were euthanized at eight time points (0, 3, 5, 8, 12, 17, 20 
and 25 days) after wax epilation. Two transgenic and two control mice were 
analyzed at each time point, and the expression level of each gene was 
measured in duplicate for each mouse.  
 
Histology 
 
 The samples of dorsal skin were fixed with Fekete’s acid-alcohol-
formalin, and embedded in paraffin blocks. Sections were stained with 
hematoxylin and eosin, and Giemsa. Slides were examined under routine light 
microscopy (Zeiss Axioskop2), and hair-follicle cycle stages were determined 
by following the guideline for the classification of murine hair follicles in 
distinct hair-cycle stages [123]. 
 
RESULTS 
 
Microarray Analysis of Gene Expression in the Skin of 
Adult K14-Agouti and Control Mice 
 
 Changes in gene expression levels in the skin of non-initiated K14-Agouti 
mice were identified using 15K Toronto cDNA microarrays. BRB-ArrayTools and 
SAM software programs were used for the analysis of microarray data. We used 
self-to-self hybridization of control samples (data not shown) for quality 
assurance of the microarray technique and the statistical analysis of data. Data 
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generated from six different hybridization experiments of skin RNA from eight-
week-old transgenic and control male mice were used collectively to identify 
genes with significantly different expression levels in K14-Agouti mice (Fig. 6).  
Microarray analysis resulted in the identification of 63 ESTs that were up-
regulated (Table A-1 in Appendix) and 118 ESTs that were down-regulated 
(Table A-2 in Appendix) in the skin of K14-Agouti mice compared to the control 
mice at the delta threshold value of 0.4 with a FDR of 22% (see Materials and 
Methods). The complete data set was deposited in NCBI’s Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and is accessible through 
GEO Series accession number GSE4641 [167]. 
 
 The identities of all 63 significantly up-regulated and an equal number of 
significantly down-regulated EST clones were determined using the NCBI Entrez 
Gene database [168]. Among the top 63 EST clones in both groups, only 40 up-
regulated clones (Table 1) and 29 down-regulated clones (Table 2) were 
associated with known genes with previously determined biological functions. 
 
qRT-PCR Analysis of the Temporal Expression Profiles of 
10 Genes in the Skin of K14-Agouti and Control Mice 
 
 Since the microarray data were from the skin of mice at a single age, we 
next selected a subset of these genes, and others, for analysis of their temporal 
expression patterns using qRT-PCR. We selected four up-regulated genes from 
the microarray results (casein kinase II, alpha 2, polypeptide, Csnk2a2; Harvey rat 
sarcoma virus oncogene 1, Hras1; platelet derived growth factor, alpha, Pdgfa; 
and plasminogen activator, urokinase receptor, Plaur) that have known functions 
associated with skin cancer biology, cellular differentiation, cellular proliferation, 
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Figure 6. Identification of significantly altered gene expression levels in the skin 
of K14-Agouti transgenic mice. Data generated from six independent microarray 
hybridization experiments with skin RNA from transgenic and control mice on 
cDNA microarrays were analyzed by SAM software as described in Materials 
and Methods. A scatter plot of the observed relative difference d(i) versus the 
expected relative difference dE(i) is shown. Solid line indicates no differential 
expression. Dashed lines mark the cutoff value for significant differential 
expression when the threshold value (delta) was 0.4 and the FDR was 22%. This 
analysis identified 181 significantly altered genes in K14-Agouti mice compared 
to non-transgenic control mice, which are plotted outside of the dashed lines. 
Out of 15,264 mouse ESTs, 63 genes were up-regulated (in red, upper-right of 
plot) while 118 genes were down-regulated (in green, lower-left of plot).   
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Table 1. List of 40 genes with known biological functions that are significantly up-
regulated in the skin of K14-Agouti mice. Shown for each gene are the GeneID 
number, gene symbol, gene name, score (d), and fold difference of gene expression 
in K14-Agouti skin compared to controls. Genes are sorted based on score (d), or d 
(i), which is assigned by the SAM program according to the change in gene 
expression relative to the standard deviation of repeated measurements. Four 
genes selected for further analysis are marked by double borders.  
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Table 2. List of 29 genes with known biological functions that are significantly 
down-regulated in the skin of K14-Agouti mice. Shown for each gene is the 
GeneID number, gene symbol, gene name, score (d), and fold difference of gene 
expression in K14-Agouti skin compared to controls. Genes are sorted based on 
score (d), or d (i), which is assigned by the SAM program according to the 
change in gene expression relative to the standard deviation of repeated 
measurements.  
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and/or hair-follicle cycle events. Additionally, we included two markers of 
cellular proliferation (proliferating cell nuclear antigen, Pcna; and telomerase 
reverse transcriptase, Tert), two markers of keratinocyte differentiation (Krt1-14 
and involucrin, Ivl), and two transcription factors (signal transducer and 
activator of transcription 1, Stat1; and signal transducer and activator of 
transcription 3, Stat3) previously shown to be up-regulated by ectopic agouti 
expression in adipose tissue [97]. Each of these 10 genes has been associated with 
skin cancer and/or other epithelial cancers (Table 3). The expression profiles of 
these genes were examined in transgenic and control mice ranging in age from 
4.5 to 26.5 weeks (Table 4).  
 
 The data in Table 4 demonstrated that all 10 genes were up-regulated in 
the skin of K14-Agouti mice compared to control mice, but not at all ages. To 
better understand the impact of K14-Agouti transgene expression on the 
expression patterns of these 10 genes, we next examined their wild-type 
temporal expression profiles in control mice (Fig. 7A and B). For this analysis, the 
expression level of each gene in the skin of 4.5-week-old control mice was 
assigned the value of 1.0 and the expression levels of each gene at all later ages 
were reported relative to this level. This analysis revealed that the wild-type 
expression profiles of these genes exhibited two general patterns. In Group I 
genes (Hras1, Krt1-14, Ivl, Pdgfa, Plaur, Stat1, and Stat3), expression remained at a 
baseline level from about 4.5-11.4 weeks of age, followed by up-regulation at 
later ages (Fig. 7A). The hair follicles of mice develop postnatally in a 
synchronous manner through two cycles of regression (catagen), resting   
(telogen), and growth (anagen), up until they are about 12 weeks old. After this 
time, hair follicles continue to cycle but in an asynchronous manner relative to 
each other [123]. The first catagen and telogen stages occur prior to 4.5 weeks of 
age, which is the youngest age of mice in which we examined gene expression
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Table 3. Summary of known functions of 10 genes with altered temporal expression patterns in the skin of K14-
Agouti mice 
Gene  
Symbol 
 
Role in Epithelial and/or Skin Cancer Biology 
 
Expression and Role During the Hair-Follicle Cycle 
Csnk2a2 Transformation of mammary epithelium due to altered expression [169]. 
Acts in casein kinase signal transduction pathway in 
keratinocytes [170]. 
Hras1 Activating point mutations are present in 30% of all human tumors; 10-20% of SCC and BCC carry an Hras1 mutation [171]. Expression peaks at early anagen [172]. 
Krt1-14 Altered expression in squamous cell skin cancer reflecting the differentiation stage [173]. 
Expressed at anagen, early differentiation marker 
[127]. 
Ivl In epidermal papillomas, expression level correlates with degree of histological differentiation [174]. 
Expressed during anagen, late differentiation marker 
[127]. 
Pcna Increased expression in squamous type skin cancers [175, 176]. Expressed in proliferating hair follicle cells [177, 178]. 
Pdgfa 
Stimulates tumor cell growth, transformation [179, 180]; expressed 
in many epithelial tumors [181, 182]; altered expression in 
squamous cell cancer [183]. 
Expressed by both FK and DPC [182]; role in 
formation of dermal papilla [184]. 
Plaur Over-expression is correlated with tumor progression and metastasis; expressed in  squamous cell skin cancers [185]. Expressed in all cells of hair follicle [186]. 
Stat1 Constitutively active in many human tumors with Stat3 [187]. Increases promoter activity of Ivl, which is a keratinocyte differentiation marker [188]. 
Stat3 Constitutively active in squamous cell cancers [183, 189, 190]; required for skin cancer development [190, 191]. 
Expressed during transition from telogen to anagen 
stage [192]. 
Tert Reactivated in 90% of human cancers [131]; telomerase-deficient mice are resistant to skin carcinogenesis [193]. Rapid transition from telogen to anagen [131]. 
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Table 4. Differential expression levels of 10 selected genes in the skin of K14-
Agouti mice compared to control mice at various ages. Fold differences for each 
gene between transgenic animals and their littermate controls are shown. 
Expression levels that are significantly up-regulated in transgenic mice based on 
qRT-PCR analysis are labeled in red. Expression levels that are significantly 
down-regulated in transgenic mice are labeled in green, and expression levels 
that do not differ significantly between transgenic and control mice are labeled in 
blue. Shown in the bottom panel are the hair-follicle cycle stages corresponding 
to the ages of C57BL/6 control mice based on the published literature [123]. The 
genes were placed into two groups based on their age-related expression 
patterns in control mice (see Fig. 7).  
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Figure 7. Age-related differences in the expression patterns of 10 genes in the 
skin of K14-Agouti mice. Gene expression levels in control mice (A and B) and 
in K14-Agouti mice relative to control mice (C and D) were determined by qRT-
PCR analysis. For control mice in graphs A and B, the expression level of each 
gene at 4.5 weeks-of-age was assigned the value of 1.0, and the expression 
levels at later ages are reported relative to this value. In graphs C and D, the 
relative fold differences between K14-Agouti and control mice are presented for 
each age. In all graphs, the y-axis represents average fold differences in gene 
expression levels (mean ± SEM), and the x-axis represents the age of mice in 
weeks. In A and B, N= 2 at 4.5, 6.4, 6.6, 7.5, 10.4, 11.4, 12.5, and 26.5 weeks of 
age and N=4 at 6.5, and 18.4 weeks of age. In C and D, N=4 at 4.5, 6.4, 6.6, 7.5, 
11.4, and 12.5 weeks of age, N=8 at 6.5 weeks of age, N=6 at 10.4 weeks of age, 
and N=2 at 26.5 weeks of age. Gene expression levels greater than 1.4 fold or 
less than 0.72 fold (each indicated by a black horizontal line) indicate significant 
changes in expression. Shown in the bottom panels are the hair-follicle cycle 
stages corresponding to the ages of C57BL/6 control mice based on the 
published literature [123]. 
 
 
 
 
 
 
 
 
 
 
 
  53
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
1
2
3
4
5
4.5 6.4 6.5 6.6 7.5 10.4 11.4 12.5 18.4 26.5
Weeks of Age 
A 
5
10
15
20
25
30
Fo
ld
 D
if
fe
re
nc
e 
0
2
4
6
8
10
12
14
16
4.5 6.4 6.5 6.6 7.5 10.4 11.4 12.5 18.4 26.5
Weeks of Age 
B 
Fo
ld
 D
if
fe
re
nc
e 
  54
Weeks of Age 
0
1
2
3
4
5
6
7
8
9
10
11
12
4.5 6.4 6.5 6.6 7.5 10.4 11.4 12.5 18.4 26.5
Fo
ld
 D
if
fe
re
nc
e 
C 
Weeks of Age 
0
1
2
3
4
5
4.5 6.4 6.5 6.6 7.5 10.4 11.4 12.5 18.4 26.5
Fo
ld
 D
if
fe
re
nc
e 
D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  55
(Fig. 7, bottom panel). Thus, the wild-type expression levels of most Group I 
genes were significantly up-regulated at a time when the hair follicles are in the 
second postnatal anagen stage (Fig. 7A). Group II genes (Csnk2a2, Pcna, and Tert) 
exhibited a cyclical wild-type pattern, with up-regulated expression possibly 
coinciding with the transitions between different hair-follicle cycle stages, or 
with other age-related differences in the skin (Fig. 7B). 
 
 Having determined the temporal expression patterns of these 10 genes in 
control mice, we next determined the relative differences in the expression levels 
of these genes in K14-Agouti mice compared to the control mice (Fig. 7C and D). 
In K14-Agouti mice, Group I genes were significantly up-regulated at three 
different time points (7.5, 10.4, and 12.5 weeks) (Fig. 7C). Thus, the expression 
levels of Group I genes were normally up-regulated in control mice during 
anagen, but in the K14-Agouti mice these genes were significantly over-
expressed during telogen, prior to the onset of anagen, and also significantly 
over-expressed at two time points during anagen. Group II genes in K14-Agouti 
mice had more of a linear profile, showing uniform over-expression during most 
of the hair-follicle cycle stages, including significant over-expression at telogen, 
prior to the onset of anagen (Fig. 7D). Taken together, these data demonstrate 
that 10 genes associated with cancer biology and/or cellular differentiation and 
proliferation events exhibited dynamic patterns of gene expression in the skin of 
control mice that change with age, and that their expression levels and patterns 
are altered in the skin of tumor susceptible K14-Agouti transgenic mice.  
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Examining Gene Expression Profiles in K14-Agouti Skin at 
Precisely Determined Stages of the Hair-Follicle Cycle 
 
 Since the agouti protein is a secreted signaling molecule normally 
expressed during anagen, we hypothesized that the observed differences in gene 
expression in K14-Agouti mice could be caused in one of two ways. First, 
constitutive over-expression of agouti could be impacting other signal 
transduction pathways, resulting in the differential expression of these genes. 
Second, over-expression of agouti could be altering the timing of the hair-follicle 
cycle stages, which in turn would alter the expression of genes associated with 
specific stages of follicle growth. To choose between these possibilities, we 
synchronized the hair-follicle cycle for all follicles in the dorsal skin of eight-
week-old K14-Agouti and control mice by hot wax epilation. At eight weeks of 
age all dorsal skin hair follicles are in telogen, and epilation induces synchronous 
anagen development of follicles over the entire epilated region, followed by the 
spontaneous entry into catagen and telogen at defined times over a 25 day period 
[123]. Mice were euthanized at eight time points (0, 3, 5, 8, 12, 17, 20 and 25 days) 
after wax epilation, the precise stage of hair follicle development was determined 
at each time point by histological examination of the skin and hair follicles, and 
qRT-PCR analysis was performed for the 10 genes at each time point.  
 
 Histological analysis of the hair follicles in K14-Agouti mice following 
synchronization showed no differences in hair-follicle cycle progress compared 
to their littermate controls. Additionally, the timing of each hair-follicle cycle 
stage for transgenic and control mice was consistent with the published literature 
for female C57BL/6 mice (Table 5).  
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Table 5. Progress of the hair-follicle cycle in K14-Agouti and C57BL/6J (B6) 
control mice. The hair-follicle cycle stages in the dorsal skin of K14-Agouti mice 
and C57BL/6J (B6) control mice are shown at eight time points (days) following 
wax epilation. Two transgenic and two control mice were euthanized at each of 
eight time-points post-epilation, and the stage of the hair-follicle cycle was 
determined by histological analysis of the skin. The hair-follicle stages did not 
differ between transgenic and control mice at any time, and they were also 
essentially the same as previously published for C57BL/6 mice (Reference B6) 
[123]. 
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 Gene expression analysis of K14-Agouti and control skin following 
epilation was performed by qRT-PCR. For each of the 10 genes, two temporal 
expression profiles are shown for the eight time-points post-epilation; the wild-
type pattern of expression in the control mice, and the relative fold differences in 
gene expression in the transgenic mice compared to the control mice (Fig. 8). For 
all genes except Stat3, wax epilation induced a significant up-regulation of wild-
type gene expression in control mice at day 3 (early anagen), which generally 
remained up-regulated at most subsequent time points. Notable among these 
nine genes were the expression patterns of Tert and Pcna. Wild-type Tert 
expression was up-regulated 3,000-fold on days 3 and 5 post-epilation (early 
anagen), followed by expression levels that ranged between 3- and 8-fold up- 
regulated on subsequent days. Wild-type Pcna expression was up-regulated 120-
fold on day 3 post-epilation and ranged between 57- and 138-fold up-regulated 
on subsequent days. 
 
 The expression levels of 7 of the 10 genes (Csnk2a2, Hras1, Krt1-14, Ivl, 
Pcna, Pdgfa, and Tert) in K14-Agouti skin were significantly up-regulated 
compared to control levels immediately after wax epilation (day 0) when dorsal 
hair follicles were in telogen (Figs. 8 and 9). The expression levels of 9 of the 10 
genes were significantly down-regulated in K14-Agouti skin compared to control 
skin during one time point in early or mid anagen (day 3: Csnk2a2, Pcna, Pdgfa, 
Plaur; day 8: Hras1, Ivl, Stat1, Stat3, Tert) (Fig. 9). With a few exceptions, the 
expression levels of the 10 genes in K14-Agouti skin did not differ significantly  
from the levels in control skin at the remaining time points. Overall, the hair-
follicle cycle synchronization experiments revealed that the initiation and 
duration of the different hair-follicle cycle stages did not differ between K14-
Agouti transgenic mice and control mice. However, the expression levels of  
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Figure 8. Temporal expression patterns of 10 genes in the skin of K14-Agouti 
mice and control mice during specific stages of the hair-follicle cycle following 
wax epilation. Gene expression levels in control mice (shown in blue) and in K14-
Agouti mice relative to control mice (shown in red) were determined by qRT-
PCR analysis. Each graph corresponds to a single gene, and the gene symbol is 
shown in the top of the graph. For each of the 10 genes, the expression level in 
control mice at day 0 after epilation was assigned the value of 1.0, and the 
expression levels at later days are reported relative to this value. In addition to 
the wild-type pattern of expression for each gene, the relative fold differences 
between K14-Agouti and control mice are shown at each time point. In all 
graphs, the y-axis represents average fold differences in gene expression levels 
(mean ± SEM), and the x-axis represents the number of days following wax 
epilation. Gene expression levels greater than 1.4 fold or less than 0.72 fold (each 
indicated by a black horizontal line) indicate significant changes in expression. 
Shown in the bottom panel are the hair-follicle cycle stages that correspond to 
each time point after wax epilation, as determined by histological analysis of the 
skin. N = 4; each gene analyzed in duplicated in two animals at each time point.  
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Figure 9. Changes in the temporal profiles of 10 genes in the skin of K14-Agouti 
mice compared to control mice following wax epilation. Genes are grouped 
according to their differential expression levels at the start of the hair-follicle 
cycle synchronization experiment and during the early and mid anagen stages of 
the hair-follicle cycle. In K14-Agouti skin, seven genes were significantly up-
regulated at day 0, four genes were significantly down-regulated at day 3, and 
five genes were significantly down-regulated at day 8.  
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many genes that are normally up-regulated in early anagen in wild-type mice 
were up-regulated at an earlier time point (telogen) in the transgenic mice. 
   
DISCUSSION 
 
 The agouti protein was previously shown to act as a tumor promoter in 
the skin of K14-Agouti transgenic mice since it promoted the development of 
papillomas in two-stage skin carcinogenesis experiments, but only after the skin 
was chemically initiated [99]. We speculated that high levels of constitutive 
paracrine signaling by agouti protein in the skin of K14-Agouti mice might act as 
a tumor promoter by in-turn up-regulating the expression of other proto-
oncogenes. Here, our goal was to determine molecular level changes in the non-
initiated skin of K14-Agouti transgenic mice using cDNA microarray and qRT-
PCR analyses. Since over-expression of agouti in the skin of K14-Agouti mice 
acts as a tumor promoter and skin tumors do not develop in the absence of 
initiation, we reasoned that any gene expression differences detected in the skin 
will possibly be associated with the promotion stage of two-stage carcinogenesis. 
 
 Through microarray analysis we identified a total of 181 differentially 
expressed genes that may be associated with the promotion stage of skin 
carcinogenesis in K14-Agouti transgenic mice. Forty of the significantly up-
regulated genes and 29 of the significantly down-regulated genes have been 
functionally annotated previously. According to their gene ontology terms, these 
differentially expressed genes are primarily involved in the following cellular 
processes: cell proliferation (Hras1, Pdgfa), regulation of progression through the 
cell cycle (Csnk2a2, Pdgfa), signal transduction (Csnk2a2, Hras1, Plaur, Erbb2 
interacting protein, Erbb2ip; guanine nucleotide binding protein (G protein), 
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gamma 3 subunit, Gng3), protein phosporylation (Csnk2a2; PTEN induced 
putative kinase 1, Pink1), regulation of peptidyl-tyrosine phosphorylation (Pdgfa), 
DNA repair (RAD1 homolog (S. pombe), Rad1; excision repair cross-
complementing rodent repair deficiency, complementation group 3, Ercc3), 
protein targeting/transport (Sec61 alpha 1 subunit (S. cerevisiae), Sec61a1, 
adaptor protein complex AP-1, beta 1 subunit, Ap1b1; Erbb2ip; AP1 gamma 
subunit binding protein 1, Ap1gbp1), ubiquitin-dependent protein catabolism 
(ubiquitin specific peptidase 27, X chromosome, Usp27x; ubiquitin specific 
peptidase 2, Usp2), regulation of transcription, DNA-dependent (zinc finger, 
matrin-like, Zfml; cartilage homeo protein 1, Cart1; c-myc binding protein, 
Mycbp), and the tricarboxylic acid cycle (malate dehydrogenase 1, NAD (soluble), 
Mdh1; citrate synthase, Cs). 
 Alterations in the first three of these cellular processes — cell proliferation, 
regulation of progression through the cell cycle, and signal transduction — are 
known to be associated with the promotion stage of carcinogenesis. Csnk2a2, 
Hras1, Pdgfa, and Plaur are each involved in at least one of these cellular 
processes, they play important roles in many normal as well as pathological 
processes, including carcinogenesis, and they were significantly up-regulated in 
the skin of K14-Agouti transgenic mice. For these reasons, we selected Csnk2a2, 
Hras1, Pdgfa, and Plaur for more detailed analyses, which included examining the 
expression levels of these genes in the skin of K14-Agouti and control mice 
ranging in age from about one month old to over six months old. We also 
examined the expression levels of these genes in the skin of two-month-old K14-
Agouti and control mice during precisely determined stages of the hair-follicle 
cycle over a 25 day period following synchronization of follicle development in 
the dorsal skin by wax epilation. In these analyses, we also included four 
markers of cellular proliferation and differentiation (Pcna, Tert, Krt1-14 and Ivl), 
  69
and two transcription factors (Stat1 and Stat3) previously shown to be up-
regulated by ectopic agouti expression in adipose tissue [97]. All 10 genes under 
investigation have previously been associated with epithelial carcinogenesis 
and/or cellular differentiation, proliferation and hair-follicle cycle events, as 
summarized in Table 3. 
qRT-PCR analysis of these 10 genes in the skin of transgenic and control 
mice over a wide range of ages revealed that, in all cases, both the expression 
levels and age-dependent dynamic expression patterns of these genes were 
altered in the skin of K14-Agouti mice. The wild-type expression levels of most 
of these genes were normally up-regulated in the skin of control mice at 12.5 
weeks of age, a time when dorsal hair follicles are in anagen, or the growth stage 
of the hair-follicle cycle. However, in K14-Agouti mice, all of these genes were 
significantly up-regulated compared to control levels at 7.5 weeks of age, a time 
that corresponds to telogen, or the resting stage of the hair-follicle cycle. For the 
majority of these genes, expression levels remained significantly elevated in the 
skin of transgenic mice compared to control mice at 10.4 weeks (early anagen) 
and 12.5 weeks (late anagen), but not at 11.4 weeks.   
The major findings from the qRT-PCR analysis of these 10 genes in the 
skin of transgenic and control mice during defined stages of the hair-follicle cycle 
following epilation are that most of these genes were significantly up-regulated 
in K14-Agouti skin compared to control skin at the telogen stage, prior to the 
onset of anagen. In control mice, wax epilation induced telogen hair follicles to 
enter anagen at three days post-epilation, which also caused a significant up-
regulation in the wild-type expression levels of 9 of the 10 genes (all except Stat3) 
during early anagen (Fig. 8; 3 days post-epilation). These results were in 
agreement with the age-dependent experiments (Fig. 7), where the wild-type 
expression levels of these genes were also up-regulated in association with the 
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transition from telogen to anagen. In K14-Agouti transgenic mice, wax epilation 
also induced telogen hair follicles to enter anagen at three days post-epilation, 
and there were no differences in hair-follicle cycling between transgenic and 
control mice. However, seven of the 10 genes (Csnk2a2, Hras1, Krt1-14, Ivl, Pcna, 
Pdgfa, and Tert) were significantly up-regulated in K14-Agouti skin compared to 
control skin during telogen (Fig. 8; 0 days post-epilation). This result also 
correlates with the age-dependent expression profiles of these genes (Fig. 7); 
namely, that the expression of K14-Agouti in the skin of mice is inducing 
significant up-regulation in the expression of genes associated with epithelial 
carcinogenesis at an earlier time (telogen) and at abnormally elevated levels 
compared to control mice. 
For nine of the 10 genes (all except Krt1-14), there was a brief period 
during early or mid anagen when their expression levels were significantly lower 
in K14-Agouti mice compared to control mice. This result may be similar to what 
we observed in mid anagen for the age-dependent experiments, where the 
expression levels of most genes did not differ significantly between transgenic 
and control mice in mid anagen (Fig. 7; 11.4 weeks). Unlike the age-dependent 
experiments, where the expression levels of all genes were significantly up-
regulated in the skin of K14-Agouti mice in late anagen (Fig. 7; 12.5 weeks), the 
expression levels of all genes did not differ significantly in transgenic and control 
mice in late anagen following epilation (Fig. 8; 12 days). The reason for this 
difference is unclear, but it suggests that, in the age-dependent experiments, 
over-expression of these 10 genes in the skin of transgenic mice in late anagen is 
associated with some age-dependent factor in the skin other than the stage of the 
hair follicles. 
Over-expression of K14-Agouti in the skin of transgenic mice had no effect 
on the hair-follicle cycle based on histological analysis of the skin, but it did 
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cause over-expression of numerous genes associated with epithelial cancers. Not 
only were these genes over-expressed in the skin of transgenic mice at ages 
associated with anagen, a time when these genes are normally activated in 
control mice, they were also over-expressed in the skin of transgenic mice during 
telogen, resulting in the exposure of transgenic skin and hair follicles to these 
proto-oncogenes over a prolonged period of the hair-follicle cycle. These results 
suggest that K14-Agouti may have a more direct role as a paracrine signaling 
molecule in altering the expression of the genes under investigation. 
Notable among the genes over-expressed in the skin of K14-Agouti mice 
are Csnk2a2, Hras1, Pdgfa, Plaur, and Stat1. Csnk2a2 is one of the catalytic subunits 
of protein casein kinase 2 (Ck2) [194]. CK2 is a pleiotropic, ubiquitously 
expressed, protein Ser/Thr kinase with 307 known substrates [195], and involved 
in many cellular functions, such as cell proliferation, division, and development 
(reviewed in [196, 197]); cell survival [198]; inhibition of apoptosis [199, 200]; and 
neoplasia (reviewed in [201]). The catalytic Csnk2a2 subunit also has oncogenic 
activity [201]. Altered expression of Csnk2a2 results in the transformation of 
mammary epithelium [169] and increases the transformation rate in fibroblasts 
[202]. 
Activation of RAS proteins initiate different signal transduction pathways 
that regulate cellular proliferation, transformation, differentiation, and apoptosis 
(reviewed in [203, 204]). Over-expression of wild-type Ras or mutations that 
constitutively activate Ras have been observed in a wide spectrum of cancers 
[205-207] including skin cancer [208, 209]. Mutations in the Hras1 gene have been 
observed in non-melonoma skin cancers with up to 20% frequency (reviewed in 
[210]). Additionally, the skin of v-Ha-ras transgenic TG.AC mice has been shown 
to have enhanced sensitivity to chemically induced tumorigenesis when there is 
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ubiquitous over-expression of agouti protein due to the presence of the Avy allele 
[21].  
PDGF and its protein tyrosine kinase receptors have been linked to a 
variety of disorders including carcinogenesis [203]. PDGF is a mitogenic protein 
and its alpha chain is known to cause transformation in both autocrine [180, 211] 
and paracrine fashions on its target cells (reviewed in [212]). Activation of 
PDGFA signaling has been shown to be critical for the development of a wide 
range of tumors such as glioblastoma, leukemia, gastro-intestinal carcinoma, 
prostate and breast cancer, malignant melanoma, and squamous cell carcinomas 
([181], reviewed in [179, 180, 183]).  
PLAUR is also involved in a wide range of physiological functions, such 
as regulation of cell surface plasminogen activity, cellular adhesion, cell motility, 
angiogenesis, wound healing, tissue regeneration, tumor invasion, and 
metastasis (reviewed in [213-215]). PLAUR and its ligand have been associated 
with malignant transformation of the ovarian epithelium [216]. Elevated levels of 
PLAUR have been reported in several malignancies ([217, 218], reviewed in [215, 
219]), including squamous cell cancer of the skin [185, 220].  
Although loss of STAT1 signaling has been shown in many human tumors 
[221, 222], it has been found to be constitutively active in a variety human tumors 
with STAT3 [188]. In squamous epithelial cells, aberrant activation of epidermal 
growth factor receptor (EGFR) has been shown to constitutively activate both 
Stat1 and Stat3 [189, 223]. Over-expression of these proto-oncogenes in the skin 
of K14-Agouti mice are highly likely to play a role in K14-Agouti-induced skin 
tumor promotion. 
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 In conclusion, we used cDNA microarray analysis to identify 181 
differentially expressed genes in the skin of K14-Agouti mice. We used qRT-PCR 
analysis to identify and quantify changes in the expression levels and temporal 
profiles of 10 genes (Csnk2a2, Hras1, Krt1-14, Ivl, Pcna, Pdgfa, Plaur, Stat1, Stat3, 
and Tert) in the skin of K14-Agouti mice, which have previously been associated 
with epithelial neoplasia in other models. These genes were significantly up-
regulated in the skin of K14-Agouti mice during telogen, prior to the normal up-
regulation of these genes during anagen in control mice. These genes were also 
over-expressed in the skin of K14-Agouti mice at ages associated with the anagen 
stage of the hair-follicle cycle, a time when agouti is normally transiently 
expressed in the skin and when mouse skin is known to be more susceptible to 
carcinogenesis. Thus, the increased susceptibility to skin carcinogenesis observed 
in K14-Agouti transgenic mice is proposed to be associated with the altered 
expression levels and patterns of these genes. Further studies with the tumor 
susceptible K14-Agouti mouse model will prove useful for extending these 
findings and for determining the molecular genetic network through which the 
unregulated activation of the agouti gene acts as a tumor promoter in skin 
carcinogenesis. 
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CHAPTER III 
 
Conclusions and Future Perspectives 
 
  
  In mice carrying the spontaneous dominant mutations Ay or Avy, 
ubiquitous over-expression of the agouti gene causes an increased susceptibility 
to tumorigenesis in numerous tissues, including the skin. These mice are also 
obese and diabetic because of ectopic agouti expression in the brain. In mice 
carrying the albumin-Agouti or K14-Agouti transgenes, over-expression of the 
agouti gene in the liver or skin, respectively, does not cause obesity or diabetes. 
However, albumin-Agouti and K14-Agouti mice are significantly more 
susceptible to liver or skin cancer, respectively, following chemical initiation of 
the liver or skin. These data suggest that the agouti protein may act as a tumor 
promoter in various tissues by directly impacting other signal transduction 
pathways in the tissue in which it is expressed. Although the association between 
the agouti protein and tumor susceptibility has been known for many decades 
and the agouti gene was cloned 14 years ago, the molecular basis of the agouti 
protein in tumorigenesis remains largely unknown. Therefore, the goal of my 
research was to elucidate molecular mechanisms associated with agouti-induced 
skin tumor promotion. 
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In the previous chapter, cDNA microarray analysis was used to identify 
significant changes in the expression levels of 181 genes in the skin of K14-
Agouti transgenic mice compared to non-transgenic control mice. Real-time qRT-
PCR experiments demonstrated that 10 genes previously associated with various 
epithelial cancers exhibited dynamic patterns of gene expression in the skin of 
control mice that changed with age, and their expression levels and patterns 
were altered in the skin of tumor susceptible K14-Agouti transgenic mice. These 
experiments provide significant insight into the potential role of the agouti 
protein as a tumor promoter in skin carcinogenesis. Taken together, these data 
suggest that over-expression of these proto-oncogenes in the skin of the 
transgenic mice are possibly associated with the increased susceptibility of K14-
Agouti mice to skin carcinogenesis. 
 
 The genes with altered expression in K14-Agouti skin can be grouped by 
gene ontology terms, which indicate the biological attributes of the gene and its 
gene product. Among the cellular processes into which these genes are grouped, 
the four with the greatest impact on tumorigenesis when they are altered in an 
individual cell are cell proliferation, DNA repair, ubiquitin-dependent protein 
catabolism, and energy metabolism. The agouti protein may act as a tumor 
promoter by altering one or more of these cellular processes.  
 
 Based on the genes that have altered expression patterns in the skin of 
K14-Agouti mice, an impact of agouti protein on cellular proliferation appears to 
be the strongest candidate for the underlying molecular mechanism of agouti-
induced tumor promotion. For example, expression of the Pdgfa, Plaur, Stat1, 
Stat3 and Hras1 proto-oncogenes was altered in K14-Agouti skin. These genes are 
regulators of cell proliferation; they act through common signal transduction 
pathways, and also interact with intracellular pathways downstream of agouti 
  76
signaling, which are mainly described in adipocytes. Additionally, even though 
there were no gross histological differences in the hair-follicle cycle between K14-
Agouti and control mice, there was an up-regulation of two cellular proliferation 
markers, Pcna and Tert, in the skin of K14-Agouti transgenic mice.  
 
 Here, I present a further dissection and analysis of the microarray results, 
and propose a model describing the main molecular mechanism for agouti-
induced skin tumor promotion. It should be noted that changes in gene 
expression levels were measured in this study, but the model focuses on the 
expected outcomes of changes in certain corresponding protein levels, which 
were not measured in this study. The model depicts the main signaling pathways 
impacted by agouti protein, the manner in which these pathways interact, and 
how alterations in these pathways would lead to increased cellular proliferation, 
which I suggest is the main molecular mechanism for agouti signaling in skin 
tumor promotion. I also suggest future experimental approaches for validation of 
the gene expression results at the protein level, and for testing of this model.  
 
MODEL SIGNAL TRANSDUCTION PATHWAYS FOR 
AGOUTI-INDUCED CELLULAR PROLIFERATION  
 
 Cells respond to different environmental signals (e.g., extracellular 
ligands, environmental changes, etc.) through different signal transduction 
pathways. The main components of a simple signal transduction pathway are an 
extracellular signal, a membrane receptor, an intracellular secondary messenger, 
and a transcription factor. Protein phosphorylation due to membrane receptor 
activation by extracellular signals initiates the signal transduction cascade. 
Protein tyrosine kinase (PTK), mitogen activated protein kinase (MAPK), and 
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protein kinase C (PKC) are three major signal transduction pathways that 
regulate numerous important cellular functions, such as homeostasis, 
proliferation, differentiation and pathophysiological processes. Constitutive 
activation of these pathways often initiates intracellular signaling pathways that 
lead to uncontrolled cellular proliferation and transformation [224]. 
 
Signal Transducer and Activator of Transcription (STAT) 
Pathway 
 
 In the skin of K14-Agouti transgenic mice, a simple model for a signal 
transduction pathway that could lead to cellular proliferation is the activation of 
the protein tyrosine kinase (PTK) pathway, via platelet-derived growth factor 
alpha (PDGFA) signaling through a PTK receptor and transduction of the signal 
by STAT mediators (Fig.10). PDGFA is a potent mitogenic signal that initiates 
intracellular signaling pathways, leading to cellular proliferation through protein 
tyrosine kinase receptors [180, 211]. It activates PDGF receptor through ligand-
mediated dimerization and auto-phosphorylation of the tyrosine residues on the 
cytoplasmic domain of the receptor. Some of the main downstream signal 
transduction molecules for PDGFA receptors are the signal transducer and 
activator of transcription (Stat) proteins [225].  
 
 Stat molecules moderate the cellular response to extracellular signals like 
cytokines and growth factors by transmitting the signal from the cell surface 
membrane to the nucleus. Upon activation of protein tyrosine kinase receptors, 
Stats are recruited by the PTK receptor and phosphorylated at the tyrosine 
residue. Phosphorylation of Stat molecules leads to homodimer or heterodimer 
formation, which directs translocation of Stats into the nucleus. In the nucleus,  
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Figure 10. Proposed mechanism for induction of STAT signaling in the skin of K14-Agouti transgenic mice. Up-
regulation of the three protein tyrosine kinase receptors (PDGFR, PLAUR, and PRLR) in the skin of K14-Agouti 
mice is proposed to induce cellular proliferation through STAT signaling. The extracellular mitogenic signals are 
delivered to the cells by Prolactin, PDGFA, and PLAU ligands, and transferred to the intracellular compartments 
by activation of PTK receptors. Activated PTK receptors induce phosphorylation of STAT molecules. 
Phosphorylated STAT molecules can form dimers and translocate to the nucleus, where they induce cellular 
proliferation. All three PTK receptors are shown on the cellular membrane, which is drawn as a bi-layered dark 
blue line. Semi-circular blue area represents the nucleus, and is surrounded by the nuclear membrane.  
Phosphorylated forms of STAT molecules are labeled with the letter P, and tyrosine residues on STAT molecules 
are marked with the letter Y. Solid arrows represent activation of signaling molecules.  
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Stats directly bind to DNA to regulate transcription of target genes, depending 
on the signaling pathway and the target tissue (reviewed in [226]). It has been 
shown that PDGF signaling can induce phosphorylation of three STAT 
molecules: STAT1, STAT3 and STAT5 (reviewed in [227]). Up-regulation of Pdgfa 
expression due to ectopic over-expression of agouti might cause over-activation 
the PTK signal transduction pathway through altered STAT activation, which is 
important in skin tumor promotion. 
 
 STATs have been shown to be constitutively activated in skin papillomas 
and SCCs [189]. Recent studies have suggested that STAT3 has an essential role 
in two-stage skin carcinogenesis, and it is required during both initiation and 
promotion events [190]. STAT3 activation through the epidermal growth factor 
receptor (EGFR), which is a PTK receptor, during the promotion stage of skin 
carcinogenesis has been shown to stimulate epidermal hyperproliferation [190]. 
Activation of EGFR and up-regulation of its ligands have been observed as a 
common response to tumor promoting agents in mouse epidermis [228, 229]. 
Besides its own PTK receptors, PDGF can phosphorylate and activate EGFR [230, 
231]. Transactivation of EGF signal by PDGF signaling has been shown to occur 
through heterodimer formation of EGFR and PDFGR [232-234]. Thus, agouti-
induced over-expression of Pdgfa could result in altered signaling through both 
PDGF and EGF receptors, which could result in increased cellular proliferation, 
as shown in Figure 10. 
 
 Intracellular STAT signaling can also be activated by cytokine signals, 
such as prolactin, through tyrosine phosphorylation of JAK kinases. Binding of 
prolactin to the prolactin receptor (Prlr), which does not have any intrinsic 
tyrosine kinase cytoplasmic domain, induces receptor dimerization, tyrosine 
phosphorylation and activation of JAK kinase, and phosphorylation of Prlr [235]. 
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Even though it was not validated by qRT-PCR, our microarray data showed that 
Prlr was up-regulated in K14-Agouti skin and had the fifth highest significance 
score. In different cell lines and tissues, PRLR has been shown to activate STAT1, 
STAT3 and STAT5. It has been suggested that prolactin activates STAT5 in a 
different manner than it does STAT1 and STAT3 [236, 237].  
 
 Plasminogen activator, urokinase receptor (Plaur), a 
glycosylphosphatidylinositol-anchored receptor, is another gene up-regulated by 
over-expression of agouti in the skin of K14-Agouti mice. PLAUR activation has 
been shown to activate different signal transduction pathways, including PTK 
[238], MAPK [239], and JAK/STAT pathways [240]. STAT1 activation through 
PLAUR has been demonstrated in a human kidney epithelial tumor line [240], 
and human vascular endothelial cells [241]. STAT1-STAT1 homodimers and 
STAT1 heterodimers with STAT2 and STAT4 have been observed upon PLAUR 
activation [242]. 
  
 In the skin of K14-Agouti mice, up-regulation of the Pdgfa ligand, and 
Plaur and Prlr receptors, could each result in altered activation of STAT 
molecules that function in PTK pathways. Additionally, up-regulation of Stat1 
and Stat3 were detected in the skin of K14-Agouti mice, which can directly 
contribute to the altered STAT signaling. Thus, unregulated STAT activation in 
the skin of K14-Agouti mice, caused by over-expression of agouti protein, is a 
candidate intracellular signaling mechanism that may lead to altered cellular 
proliferation (Fig. 10).  
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Mitogen Activated Protein Kinase (MAPK) Pathway 
 
 A variety of extracellular stimuli, such as environmental stress, mitogens, 
cytokines, and neurotrophins can be transmitted to the nucleus through 
intracellular mitogen activated protein kinase (MAPK) pathway signaling 
cascades (reviewed in [203, 243, 244]). Although the mechanisms that control the 
specificity of the cellular response to different stimuli through MAPK pathways 
are still not clear, regulation of cellular proliferation through Ras-mediated 
Raf/MEK/ERK signaling has been demonstrated in many studies (reviewed in 
[171, 245-248]). One of the major activators of Ras/ERK signaling is the 
phosphorylation of Ras by downstream mediators of PTK receptors [249]. Active 
Ras recruits Raf-1 to the plasma membrane, where it will be activated by 
phosphorylation [250]. In the next step of the cascade, Raf-1 directly activates 
MEK, which is followed by ERK phosphorylation [251]. As discussed above, 
PDGFA, PLAUR, and PRLR signals are activators of PTK signal transduction 
pathways. For all three molecules, activation of the Raf/ERK signaling cascade 
was previously proposed to explain effects of these signals on cellular 
proliferation [235, 239, 252, 253]. 
 
 The Hras1 proto-oncogene is up-regulated in the skin of K14-Agouti mice. 
In addition to the activators of PTK signaling pathways, over-expression of wild-
type Ras or activated Ras mutations is associated with tumorigenesis in different 
tissues [205-209]. Ras/Erk is a target pathway in tumor promotion, as altered 
regulation of mitogenic Ras/ERK signaling provides a growth advantage to the 
target cells.  
 
 STAT activation, induction of the Ras/ERK MAPK pathway through PTK 
receptors, and over-expression of Hras1 may be independent but interacting 
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molecular mechanisms that could lead to altered cellular proliferation resulting 
from altered agouti signaling (Figure 11).  
 
Protein Kinase C (PKC) Pathway 
 
 Protein kinase C (PKC) signaling has been shown to induce the Raf-
1/MEK/ERK signaling pathway through activation of the Raf-1 molecule [254-
256], which has been proposed as the key mediator connecting PTK signaling 
through growth factor receptors (such as PDGFR and EGFR) and PKC signals at 
the cell membrane [257, 258].  
 
 PKC signaling has been implicated in the control of different cellular 
functions, including cellular proliferation [249, 259, 260], and over-activation of 
PKC signaling can result in cellular transformation [261-263]. The conventional 
PKC isoforms, PKCα, PKCβ, and PKCγ, are diacylglycerol (DAG) sensitive, and 
calcium responsive. This group of PKCs are activated by increased intracellular 
Ca2+ levels due to Ca2+ influx through Ca2+ channels or due to release of Ca2+ 
from intracellular stores [264, 265]. PKC translocates to the membrane after 
binding to Ca2+ to interact with DAG, which transforms PKC into a fully active 
enzyme. PKCα has been reported to phosphorylate and activate Raf [251, 256, 
266, 267], which then activates ERK and transmits a PKC-dependent proliferation 
signal ([263, 268], reviewed  in [269]).  
 
 Activation of PKC in response to a sustained increase in intracellular 
calcium levels contributes to insulin resistance [249], which is also a possible 
mediator for the insulin resistance observed in Avy mice [89, 270]. Similar to 
calcium-mediated PKC activation in insulin resistance, agouti might be
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Figure 11. Intracellular signal transduction pathways proposed to be activated in K14-Agouti skin in response to 
agouti signaling.  Activation of two intracellular signal transduction pathways, STAT and RAF/ERK, are proposed 
to induce cellular proliferation in K14-Agouti skin. STAT signaling can be activated through protein tyrosine 
kinase receptors (PDGFR, PLAUR, and PRLR) (Fig. 10), which is labeled as PTKR. In this model, over-expression of 
agouti is proposed to activate a calcium-dependent PKC pathway, which in turn can activate Ras-independent 
ERK signaling. ERK signaling can also be initiated by activation of either PTKR or RAS molecules in the skin of 
K14-Agouti mice. MCR, Ca2+ channels, and PTKRs are shown on the cellular membrane, which is drawn as a bi-
layered dark blue line. Semi-circular blue area represents the nucleus, and is surrounded by the nuclear membrane.  
Phosphorylated forms of STAT molecules are labeled with the letter P and tyrosine residues on STAT molecules 
are marked with the letter Y. Solid arrows represent activation of signaling molecules.  
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activating PKC signaling through Ca2+-dependent pathways. Therefore, agouti-
induced cellular proliferation through PKC/ERK signaling is another mechanism 
that may contribute to the tumor susceptibility phenotype in K14-Agouti, Ay, and 
Avy mice (Figure 11).  
 
 Agouti-dependent elevation of intracellular Ca2+ has been observed in 
several different cell types, such as skeletal muscle myocytes [93], adipocytes 
[95], and pancreatic beta cells [271]. Agouti has been shown to act through both 
Ca2+ transportation channel-dependent [95], and melanocortin receptor-
dependent pathways [89] to increase intracellular Ca2+ levels. Although agouti 
can act through both Ca2+ channels and melanocortin receptors for Ca2+-
dependent PKC activation, signaling through Ca2+ channels may be more likely 
to explain the fact that over-expression of agouti throughout the body of Ay and 
Avy mice causes increased tumor susceptibility in numerous tissues. For example, 
agouti has been shown to cause a slow increase in intracellular Ca2+ levels only 
through MC1R and MC4R receptors, which are expressed in the skin and 
hypothalamus, respectively. On the other hand, Ca2+ channel receptors are 
ubiquitously expressed in many different tissues. Thus, PKC activation through 
Ca2+ channel receptors would not be limited to specific tissues, presenting a 
molecular mechanism that could explain tumor susceptibility in different tissues 
due to ectopic agouti signaling. 
  
 Agouti protein and the phorbol ester, 12-O-tetradecanoyl-phorbol-13-
acetate (TPA), are each tumor promoters in the skin of K14-Agouti mice. 
Additionally, the agouti and TPA tumor promoters act synergistically in the skin 
of K14-Agouti mice, decreasing the latent period of tumor formation and 
increasing the cumulative prevalence, multiplicity, and malignant conversion 
rate of skin papillomas [99]. It was suggested that agouti and TPA promote 
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tumor development through independent pathways, but that these pathways 
ultimately converge and lead to enhanced skin tumor promotion and 
progression [99]. In addition to the activation of conventional calcium-dependent 
PKCs by TPA, calcium-independent PKCδ can be induced in response to TPA 
treatment. TPA has been shown to regulate cellular hyperplasia through PKCδ 
induced Raf/ERK activation, as over-expression of c-Raf increases activation of 
Ras-independent MAPK signaling in response to TPA treatment [255]. TPA and 
agouti might be inducing independent intracellular signals through PKCδ and 
calcium-dependent PKCs, respectively, which in turn could activate Ras/Erk 
signaling in both cases. Therefore, the proposed mechanism for agouti-induced 
cellular proliferation through Ca2+-dependent PKC activation might also be the 
molecular basis of the synergistic action of TPA and agouti in tumor promotion.  
 
 The induction of the STAT, MAPK and PKC signaling pathways by 
altered agouti signaling could each initiate cellular proliferation independently, 
in an additive manner, or these three pathways might be interacting with each 
other to amplify the cellular proliferation signal transmitted to the nucleus (Fig. 
11). 
 
Regulation of Gene Expression through Protein Kinase C   
  
 The Plaur, Pdgfa, Stat1, and Stat3 genes, which are up-regulated in K14-
Agouti skin due to over-expression of agouti, have also been shown to be 
regulated at the transcriptional level by phorbol esters, specifically, by TPA. 
Activation protein 1 (AP-1) is a group of transcriptional activator genes, 
including the c-fos and c-jun oncogenes, which are the early responding genes to 
TPA-induced PKC activation [272]. When activated, AP-1 proteins form dimers 
through their basic region-leucine zipper binding motif, which can recognize and 
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bind to TPA-response elements (TRE) found in the promoters of TPA-inducible 
secondary response genes ([273], reviewed in [274]).   
 
 The PDGFA gene was shown to be induced by phorbol esters in human 
glomerular mesangial cells [275] through TREs 1 and 2 in the promoter of 
PDGFA ([276, 277], reviewed in [278]). Additionally, phorbol ester and TPA-
induced activation of Plaur transcription has been shown during the promotion 
stage of skin carcinogenesis, and in papillomas and carcinomas of mouse skin 
[224, 279, 280, 281 ]. Plaur expression is induced in response to phorbol esters, 
along with other urokinase genes, through PKC activation [279, 280]. Two 
different AP-1 binding sites in the promoter region of human Plaur were 
mapped, and induction of uPAR expression by phorbol esters was shown to 
require the AP-1 binding site in colon cancer cells [282]. As they are induced by 
the tumor promoting agent TPA, expression of urokinase genes by epithelial and 
stromal cells has been suggested to have an impact on the early steps of tumor 
promotion [220, 279].   
 
 In a recent study, activation of STAT1 and STAT3 transcription factors 
was observed in skin papillomas and SCCs after topical treatment with different 
tumor promoters, including TPA. In primary mouse keratinocyte cultures, an 
EGFR-dependent activation mechanism was demonstrated for TPA-induced 
Stat3 transcription. However, the involvement of TPA-induced PKC activation in 
transcriptional regulation of Stat1 and Stat3 still needs to be determined [189].  
 
 Transcription of Pdgfa and Plaur were up-regulated in the skin of K14-
Agouti mice in response to the over-expression of agouti protein. TPA has been 
shown to induce transcriptional activation of both Pdgfa and Plaur through 
activation of PKC. Agouti and TPA act synergistically during the promotion 
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stage of skin carcinogenesis in K14-Agouti mice [99]. Therefore, it is possible that 
agouti-induced up-regulation of Pdgfa and Plaur transcription in the skin of K14-
Agouti mice might be occurring through a PKC-activated signaling pathway. 
Up-regulation of the transcription of the Pdgfa and Plaur proto-oncogenes could 
be inducing altered signal transduction through the STAT and MAPK pathways, 
which could generate aberrant cellular proliferation signals. 
 
In conclusion, I propose that agouti protein, like many other proto-
oncogenes, may act as a tumor promoter by altering cellular signaling pathways 
that induce the proliferation of initiated cells. In Figure 12, I present a model for 
the role of agouti protein in cellular proliferation, which includes all of the 
proposed intracellular signaling pathways and interactions that were discussed 
above. 
 
FUTURE PERSPECTIVES 
 
 
 In this study, I have shown differential expression of a set of genes in the 
skin of tumor susceptible K14-Agouti transgenic mice that have known roles in 
skin and/or other epithelial cancers. Based on the genes identified in these 
experiments, on their established roles in normal cellular processes and common 
signaling pathways, and on the known roles of agouti signaling in pigmentation 
and obesity, I have proposed a hypothetical model to explain the role of the 
agouti protein in tumor promotion. The model predicts that agouti may function 
as a tumor promoter by altering various intracellular signaling pathways that 
lead to unregulated cellular proliferation of initiated cells (Figure 12). Here, I 
briefly describe several experimental approaches to test the validity of this model 
and the proposed role of the agouti protein in tumor promotion.  
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Figure 12: Proposed model for intracellular signaling pathways involved in 
agouti-induced cell proliferation during tumor promotion. The main interactions 
between three signaling pathways (calcium dependent PKC, Raf/ERK and 
STAT) are shown in respect to each other. Genes that were found to be 
differentially expressed in K14-Agouti skin are shown in red. Pathway activation 
is represented with solid lines. Dashed lines indicate activation of gene 
transcription. Over-expression of agouti signaling activates calcium dependent 
PKC, which turns on transcription of Pdgfa and Plaur. Additionally, agouti 
signaling might be activating the transcription of Stat1 and Stat3 through PKC 
signaling. Altered levels of PDGFA and PLAUR proteins have the potential to 
induce cellular proliferation through both STAT and RAS-RAF/ERK signal 
transduction pathways. The RAF/EEK pathway can also be activated by PKC, 
and by over-expression of the Ras proto-oncogene.  
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 In the proposed model, increased transcription of Pdgfa and Plaur in the 
skin of K14-Agouti mice are considered to be the earliest events, which will then 
trigger activation of STAT and Raf/Erk signaling, resulting in increased cellular 
proliferation as determined by increases in the expression levels of cellular  
proliferation markers. The sequential expression of these genes can be examined 
by determining their order of activation after agouti stimulation of keratinocytes 
in a cell culture system, which is a well-established in vitro model system to 
study mouse skin biology and carcinogenesis [266, 283-286]. Changes in gene 
expression patterns at different time points following treatment of keratinocytes 
with recombinant agouti protein can be determined by qRT-PCR analysis. 
Examining a time-course of gene expression differences in keratinocytes 
following agouti stimulation would allow us to identify early and late 
responding genes, and to test the proposed model. The most important finding 
among the possible outcomes of this set of experiments would be the timing of 
expression of Pdgfa and Plaur compared to the other genes. I would expect to 
observe changes in the expression of Pdgfa and Plaur immediately following 
agouti protein stimulation, while up-regulation of the proliferation markers, Pcna 
and Tert, should occur at a later time for the proposed model to be valid. 
Determining the exact timing and order of the regulation of Stat1, Stat3, Hras1, 
Pcna and Tert will be helpful for fine-tuning the proposed interactions between 
the various signaling pathways.  
 
 Establishing differential regulation of these genes in keratinocyte cultures 
after treatment with recombinant agouti protein will provide us with a tractable 
system for following and testing the effects of agouti protein on calcium, PKC, 
and Raf/Erk signaling. First, it will be necessary to establish that treatment of 
keratinocytes with recombinant agouti protein will induce an increase in 
intracellular calcium levels (as it does in some other cell types), and activation of 
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PKC and Raf/Erk molecules. Then each of these three intracellular signals can be 
inhibited individually to determine their contribution to the overall picture, in 
which the end results can be followed by the measurements of Pcna and/or Tert 
expression, and cellular proliferation rates. During each inhibition experiment, 
analysis of the regulation of gene expression and the changes in the activation 
levels of the other two pathways will provide us with the necessary information 
to elucidate the dependence of these events on each other. For example, 
according to the model, when elevation of intracellular calcium is inhibited, PKC 
and Erk signaling, and the expression of Pcna and Tert should not be activated to 
the same levels as determined previously. Additionally, according to the 
proposed model, agouti induces transcription of Pdgfa and Plaur through 
activation of calcium-dependent PKC signaling.  So, if this model is accurate, we 
would not expect to see any significant changes in the transcription of Pdgfa and 
Plaur in response to agouti signal when intracellular calcium and/or PKC 
signaling is inhibited. On the other hand, inhibition of Erk signaling should not 
affect the increase in intracellular calcium levels, the activation of PKC, or the 
transcription of Pdgfa or Plaur after treatment of keratinocytes with recombinant 
agouti protein.  
 
 Parallel to the experimental approaches described above, different 
keratinocyte cell lines deficient for Hras1, Pcna, Pdgfa, Plaur, Stat1, Stat3, and Tert 
can be generated in vitro by RNA mediated interference (RNAi), where long-term 
post-transcriptional inhibition of targeted mRNA can be achieved by transfection 
of cells with small interfering RNA duplexes (siRNA) expressed under the 
control of RNA Polymerase III [287-290]. Observation of changes in the activation 
of different signaling pathways, and regulation of other genes will provide 
valuable information about the contribution of each gene in the different 
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signaling pathways, and identify the key players of the proposed signaling 
pathway.  
 
 Changes in gene expression levels determined by qRT-PCR should be 
confirmed at the protein level. Additionally, analysis of the phosphorylation 
status of STAT, RAF and ERK proteins would be important to determine their 
activity levels. Western blot analysis is the classical approach for determination 
of single protein expression and phosphorylation levels, which should be the 
first choice in the analysis of a small set of genes, like in our experiments.  
However, identification of overall changes in the protein expression levels, and 
the post-translational modifications to these proteins with high-throughput 
techniques will also be valuable. While complementing the results of the 
microarray experiments, comparisons of changes in gene and protein levels will 
provide additional important information about the regulatory dynamics of the 
signaling pathways impacted by agouti signaling. Such comparisons may prove 
useful for mapping the signaling networks associated with agouti-induced tumor 
promotion [291].   
 
 Protein arrays, two-dimensional differential fluorescence gel 
electrophoresis (DIGE), and mass spectrometry are some of the high-throughput 
approaches that can be used for protein expression profiling. Protein arrays are 
produced by fixing antibodies on slides that are highly specific for their target 
proteins. When these arrays are treated with protein samples from tissues or cell 
cultures, proteins are bound by the antibodies to the array surface, which then 
can be detected with systems such as the streptoavidin-biotin complex. 
Comparison of protein binding levels between the experimental and control 
samples allows detection of the differentially expressed proteins [292, 293]. In the 
DIGE system, similar to cDNA microarray analysis, experimental and control 
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samples are labeled either with Cy3 or Cy5. Following 2D gel electrophoresis, 
where each protein is separated according to its charge and mass, each sample is 
individually imaged and measurements are compared in order to determine the 
expression levels of each protein in the experimental and control samples. An 
additional advantage of the DIGE system is that it has the capacity for detecting 
many different post-translational modifications of proteins, including 
phosphorylation status [294]. DIGE analysis can be followed by mass 
spectrometry technology for identification of proteins of interests. Additionally 
different mass spectrometry approaches such as stable isotope labeling and 
quantification using the absolute peptide ion intensity can be utilized for global 
protein analysis and identification of differential protein expression profiles [295, 
296]. 
 
 Findings of these experimental approaches should help us to accept, 
modify, or reject the proposed model. The new information gathered about 
agouti signaling should be used to adjust the shortcomings of the proposed 
model or to propose a new model.  
 
 After identification of the intracellular signaling pathways activated by 
agouti protein, the next challenge will be to demonstrate the role of the described 
signaling pathways in tumor promotion. Several of the reagents generated 
during elucidation of the signaling pathways impacted by agouti protein can be 
utilized in this effort. Comparison of in vitro cellular proliferation rates of agouti 
treated keratinocytes in which calcium, PKC, or Raf/Erk signaling is inhibited 
will be informative about the contribution of these signaling molecules on 
agouti-induced cell proliferation. Furthermore, determination of changes in the 
cellular proliferation rates in each RNAi keratinocyte cell line deficient for Hras1, 
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Pcna, Pdgfa, Stat, Stat1, Stat3, or Tert will establish the individual roles of these 
genes.  
 
 In vitro colony (focus) formation assays and in vivo transplantation of cells 
into nude mice are widely used experimental approaches for the analysis of 
tumorigenic capacity. These assays test the ability of cultured cells to form 
tumors after growth in a semisolid agarose bilayer in a petri dish or in athymic 
nude mice, respectively. In the colony formation assay, cells in culture started 
from a single cell are grown in soft agar and the rate of colony formation is 
measured. Similarly, cells can be injected subcutaneously into immunodeficient, 
hairless mice and their tumorigenic capacity can be measured by monitoring the 
formation of papillomas and squamous cell carcinomas. Since agouti is a tumor 
promoter, the tissues or cell cultures that are over-expressing the agouti signal 
will not give rise to increased numbers of tumors unless the cells are first 
initiated. Therefore, to be able to measure the differences in the tumorigenic 
capacities of the different cell lines in either assay, initiation of the cultured cells 
will be necessary.  In order to overcome these problems and ensure the stability 
of introduced changes like gene silencing, and to eliminate the agouti treatment 
of the cell cultures, K14-Agouti mice can be crossed with mice null for several of 
the selected genes that showed potential to be the key players in agouti signaling 
in the previous experiments. These new transgenic lines, which are over-
expressing agouti in the skin but deficient for one of the agouti-regulated genes, 
can be used for two-stage carcinogenesis. Any significant decrease in the rate of 
papilloma formation after initiation of the skin with a single DMBA application 
in the presence of over-expressed agouti signaling should demonstrate the 
importance of the knockout gene(s) during tumor promotion.  
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  K14-Agouti transgenic mice represent a model system in which changes 
associated with the tumor promotion stage of skin carcinogenesis can be 
examined before the development of tumors. Such a model is useful for 
elucidating molecular mechanisms associated with the promotion stage of 
carcinogenesis. Since a large number of genetic changes will have occurred after 
the development of a skin tumor, it can be difficult to determine which molecular 
changes in tumors are associated with the promotion stage of tumor 
development. Elucidating the molecular mechanisms associated with tumor 
promotion is important, as tumor promotion is a reversible and rate-limiting 
event in carcinogenesis. The studies described here will provide insights into the 
mechanisms underlying agouti-induced tumor promotion. Ultimately, our goal 
is to achieving a better understanding of the promotion stage of carcinogenesis, 
which may provide new tools to better predict the risk factors associated with 
carcinogenesis, and to develop mechanistic-based strategies for prevention and 
treatment of cancer.   
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Table A-1: List of significantly up-regulated EST clones 
 
 
GenBank 
Accession Score (d) 
Fold 
Difference 
1 BG069401 4.65 5.12 
2 AW554157  4.23 2.71 
3 BG064629 4.00 2.40 
4 BG076699 3.69 2.78 
5 BG069435 3.65 1.81 
6 BG076669 3.60 3.24 
7 BG069801  3.58 1.97 
8 BG084801 3.56 3.37 
9 BG068870 3.55 2.13 
10 BG062978 3.54 2.70 
11 BG078960 3.54 6.45 
12 BG069400 3.48 2.16 
13 BG068914 3.39 2.24 
14 BG075404 3.31 1.98 
15 BG066780 3.29 1.60 
16 BG067185 3.20 2.23 
17 BG070933 3.19 1.70 
18 BG074710 3.19 2.51 
19 BG067379 3.15 1.81 
20 BG065574 3.15 2.15 
21 AU045245 3.14 2.19 
22 BG078140 3.10 2.69 
23 BG075278 3.09 1.70 
24 BG072416 3.06 1.90 
25 BG081040 3.05 1.40 
26 C78141 3.03 1.45 
27 BG063752 3.00 2.34 
28 BG072139 2.99 1.50 
29 BG074480 2.98 2.30 
30 BG065258 2.96 1.82 
31 BG065416 2.95 2.36 
32 BG075652 2.92 1.93 
33 BG068523 2.91 2.00 
34 AU040544 2.90 2.00 
35 BG087899 2.89 1.76 
36 BG073401 2.89 1.78 
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Table A-1 Continued 
 
 
GenBank 
Accession Score (d) 
Fold 
Difference 
37 BG075147 2.89 2.26 
38 AW546368 2.88 2.26 
39 BG074375 2.87 2.12 
40 AW558391 2.87 2.54 
41 BG074155 2.82 2.28 
42 BG065550 2.78 1.50 
43 BG075009 2.78 1.53 
44 BG078271 2.76 2.53 
45 BG063602 2.76 1.77 
46 BG085480 2.75 1.69 
47 BG077083 2.75 1.87 
48 BG078778 2.74 1.67 
49 BG074261 2.74 2.49 
50 BG069140 2.73 1.70 
51 BG070161 2.73 1.43 
52 BG088153 2.72 1.45 
53 BG075704 2.72 1.66 
54 BG069963 2.71 2.38 
55 AW559010 2.71 7.59 
56 BG065751 2.70 1.83 
57 BG073392 2.69 2.02 
58 BG077751  2.67 1.46 
59 BG063024 2.67 2.55 
60 AW556849 2.67 2.42 
61 BG064824 2.66 1.88 
62 BG075661 2.65 1.83 
63 BG069325 2.64 2.10 
 
 
 
 
 
 
 
 
 
 
  119
 
Table A-2: List of significantly down-regulated EST clones 
 
 
GenBank 
Accession Score (d) 
Fold 
Difference 
1 BG080756 -4.94 0.22 
2 BG067459 -4.85 0.46 
3 BG069326 -4.19 0.21 
4 BG070908 -3.88 0.32 
5 BG068321 -3.79 0.35 
6 BG080961 -3.73 0.39 
7 BG070437 -3.71 0.48 
8 BG078393 -3.67 0.20 
9 BG068281 -3.62 0.36 
10 BG079049 -3.60 0.48 
11 BG063061 -3.58 0.17 
12 BG068227 -3.52 0.26 
13 BG067575 -3.44 0.22 
14 BG064789 -3.41 0.48 
15 BG080372 -3.34 0.54 
16 BG063376 -3.23 0.26 
17 BG088216 -3.20 0.51 
18 BG072510 -3.18 0.48 
19 AA408197 -3.16 0.38 
20 BG072581 -3.15 0.71 
21 BG071958 -3.13 0.50 
22 BG080565 -3.10 0.51 
23 BG064250 -3.09 0.50 
24 BG072525 -3.09 0.57 
25 BG066404 -3.08 0.42 
26 BG069987 -3.06 0.44 
27 BG083259 -3.05 0.10 
28 C85855 -3.02 0.36 
29 BG080525 -2.98 0.50 
30 BG070488 -2.96 0.62 
31 BG068092 -2.96 0.45 
32 BG065639 -2.95 0.44 
33 BG082362 -2.95 0.43 
34 BG072458 -2.94 0.31 
35 BG072229 -2.94 0.47 
  120
Table A-2 Continued 
 
 
GenBank 
Accession Score (d) 
Fold 
Difference 
36 BG076569 -2.92 0.28 
37 BG080868 -2.91 0.33 
38 BG082009 -2.91 0.38 
39 BG067579 -2.90 0.28 
40 BG066639 -2.89 0.22 
41 AW558635 -2.89 0.40 
42 BG067060 -2.87 0.61 
43 BG069223 -2.86 0.27 
44 BG072807 -2.86 0.42 
45 BG067577 -2.86 0.63 
46 BG065984 -2.83 0.49 
47 BG067544 -2.82 0.61 
48 BG086567 -2.82 0.50 
49 BG063733 -2.81 0.32 
50 BG084279 -2.81 0.48 
51 BG066515 -2.80 0.39 
52 BG088837 -2.80 0.48 
53 BG070073 -2.80 0.42 
54 BG070961 -2.79 0.24 
55 BG066695 -2.79 0.42 
56 BG073477 -2.79 0.13 
57 BG066036: -2.78 0.47 
58 C87415 -2.78 0.56 
59 AU018797 -2.76 0.21 
60 AU043030 -2.76 0.41 
61 BG068421 -2.75 0.33 
62 C80656 -2.75 0.56 
63 BG078783 -2.75 0.50 
64 BG082144 -2.73 0.67 
65 BG078394 -2.71 0.43 
66 BG066960 -2.70 0.61 
67 BG063430 -2.69 0.38 
68 BG064752 -2.69 0.50 
69 BG063715 -2.68 0.53 
70 BG082354 -2.68 0.43 
71 BG076744 -2.67 0.37 
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GenBank 
Accession Score (d) 
Fold 
Difference 
72 BG067204 -2.66 0.42 
73 BG065962 -2.65 0.50 
74 BG083351 -2.65 0.25 
75 AW545830 -2.64 0.62 
76 BG067124 -2.64 0.26 
77 BG076025 -2.64 0.59 
78 BG069716 -2.62 0.60 
79 BI076595 -2.61 0.54 
80 BG066161 -2.60 0.48 
81 BG068687 -2.60 0.49 
82 BG066468 -2.59 0.33 
83 BG068412 -2.59 0.58 
84 BG084956 -2.56 0.49 
85 BG065203 -2.55 0.45 
86 BG086529 -2.55 0.64 
87 BG065689 -2.53 0.62 
88 BG069589 -2.53 0.40 
89 BG078672 -2.51 0.44 
90 BG088006 -2.51 0.59 
91 AW556334 -2.50 0.15 
92 BG067320 -2.50 0.57 
93 BG068547 -2.50 0.29 
94 BG081646 -2.50 0.53 
95 AW555555 -2.49 0.44 
96 BG068764 -2.49 0.40 
97 BG076373 -2.49 0.48 
98 AU018221 -2.48 0.54 
99 AU022767 -2.48 0.20 
100 BG075725 -2.48 0.57 
101 AU022997 -2.47 0.38 
102 BG066568 -2.47 0.38 
103 BG067890 -2.47 0.49 
104 BG068433 -2.46 0.52 
105 BG069583 -2.46 0.62 
106 BG073971 -2.46 0.35 
107 BG080589 -2.46 0.38 
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GenBank 
Accession Score (d) 
Fold 
Difference 
108 AA408305 -2.45 0.36 
109 AW547303 -2.45 0.40 
110 BG067557 -2.45 0.62 
111 BG072014 -2.45 0.67 
112 BG083842 -2.45 0.60 
113 BG063053 -2.44 0.33 
114 BG065759 -2.44 0.69 
115 BG084201 -2.44 0.43 
116 BG068506 -2.43 0.73 
117 BG073713 -2.42 0.59 
118 BG083368 -2.42 0.62 
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